

# NHS BLOOD AND TRANSPLANT

## NATIONAL LIVER OFFERING SCHEME

### NINETY MONTH REVIEW

#### SUMMARY

##### **1. BACKGROUND**

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity.
- 1.2. It should be noted that this report may not include all data due to delays in reporting.
- 1.3. Updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in **Figure 9B**.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and the changes to the DBD offering scheme ceased on 9 July 2020 when named patient offering recommenced. This period is excluded from part of the liver offering section.
- 1.5. The estimates used to calculate the Transplant Benefit Score (TBS) were updated on 4 October 2022 and the offering data has been presented separately for 2022/2023. One of the factors (inpatient status) identified as statistically significant in the non-cancer models was set to zero on 23<sup>rd</sup> May 2023 following discussion at the prior NLOS monitoring committee and LAG Core Group.

## 2. DATA AND METHODS

2.1. **Table S1** shows the time period and inclusion and exclusion criteria for the aspects of the offering scheme examined in this report. NHS Group 2 registrations and transplants were excluded throughout the report along with registrations, offers and transplants for intestinal patients not requiring a liver. Super-urgent and elective registrations were included in all aspects apart from the transplant list activity section as were adult and paediatric registrations and transplants. All full year time periods are 20 March to 19 March.

<b>Table S1</b> Inclusion and exclusion criteria for the aspects of NLOS examined in this report			
<b>Section</b>	<b>Time period</b>	<b>Inclusions</b>	<b>Exclusions</b>
Registration activity	<ul style="list-style-type: none"> <li>20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=1169)</li> <li>20 March 2018 to 19 September 2025 (<i>ninety month post</i>, N=8740)</li> </ul>	<ul style="list-style-type: none"> <li>New active/suspended registrations</li> </ul>	<ul style="list-style-type: none"> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> </ul>
One and three month post-registration outcome	<ul style="list-style-type: none"> <li>20 December 2014 to 19 December 2017 (<i>Year prior</i>, N=2779)</li> <li>20 March 2018 to 19 June 2025 (<i>eighty-seven months post</i>, N=6938)</li> </ul>	<ul style="list-style-type: none"> <li>Active and suspended</li> <li>Adult elective liver and liver/kidney registrations</li> </ul>	<ul style="list-style-type: none"> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> <li>Intestinal registrations</li> </ul>
Six months post-registration outcome	<ul style="list-style-type: none"> <li>20 September 2014 to 19 September 2017 (<i>Year prior</i>, N=2781)</li> <li>20 March 2018 to 19 March 2025 (<i>eighty-four months post</i>, N=6703)</li> </ul>	<ul style="list-style-type: none"> <li>Active and suspended</li> <li>Adult elective liver and liver/kidney registrations</li> </ul>	<ul style="list-style-type: none"> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> <li>Intestinal registrations</li> </ul>
One-year post-registration outcome	<ul style="list-style-type: none"> <li>20 March 2014 to 19 March 2017 (<i>Year prior</i>, N=2808)</li> <li>20 March 2018 to 19 September 2024 (<i>seventy-eight months post</i>, N=6238)</li> </ul>	<ul style="list-style-type: none"> <li>Active and suspended</li> <li>Adult elective liver and liver/kidney registrations</li> </ul>	<ul style="list-style-type: none"> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> <li>Intestinal registrations</li> </ul>
Two-year post-registration outcome	<ul style="list-style-type: none"> <li>20 March 2014 to 19 March 2016 (<i>Year prior</i>, N=1884)</li> <li>20 March 2018 to 19 September 2023 (<i>sixty-six months post</i>, N=5330)</li> </ul>	<ul style="list-style-type: none"> <li>Active and suspended</li> <li>Adult elective liver and liver/kidney registrations</li> </ul>	<ul style="list-style-type: none"> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> <li>Intestinal registrations</li> </ul>
Liver offering	<ul style="list-style-type: none"> <li><i>Year prior</i>, N=1914 (962 DBD and 952 DCD)</li> <li><i>Ninety months post</i>, N=12838 (6147 DBD and 6691 DCD)</li> </ul>	<ul style="list-style-type: none"> <li>UK deceased donors whose liver was offered for transplantation</li> <li>Offers to Dublin for super-urgent patients</li> </ul>	<ul style="list-style-type: none"> <li>Intestinal offers regardless of whether patients required a liver</li> <li>Offers declined due to the patient accepting previously offered liver</li> <li>Offers to Dublin for elective patients</li> </ul>
Transplant activity	<ul style="list-style-type: none"> <li>20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=1017, 819 DBD and 198 DCD)</li> <li><i>Ninety months post</i>, N=6623 (4924 DBD and 1699 DCD)</li> </ul>	<ul style="list-style-type: none"> <li>UK transplants</li> </ul>	<ul style="list-style-type: none"> <li>Transplants performed at Dublin</li> <li>Intestinal transplants for patients not requiring a liver</li> <li>NHS Group 2 transplants</li> </ul>
Ninety-day post-transplant survival	<ul style="list-style-type: none"> <li>20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=579 for DBD and 183 for DCD)</li> <li>20 March 2018 to 19 June 2025 (<i>Eighty-seven months post</i>, N=3494 for DBD and 1490 for DCD)</li> </ul>	<ul style="list-style-type: none"> <li>UK adult elective liver and liver/kidney transplants</li> </ul>	<ul style="list-style-type: none"> <li>Txs performed at Dublin</li> <li>Intestinal transplants for patients not requiring a liver</li> <li>NHS Group 2 transplants</li> </ul>
One-year post-transplant survival	<ul style="list-style-type: none"> <li>20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=579 for DBD and 183 for DCD)</li> <li>20 March 2018 to 19 September 2024 (<i>seventy-eight months post</i>, N=3032 for DBD and 1257 for DCD)</li> </ul>	<ul style="list-style-type: none"> <li>UK adult elective liver and liver/kidney transplants</li> </ul>	<ul style="list-style-type: none"> <li>Txs performed at Dublin</li> <li>Intestinal transplants for patients not requiring a liver</li> <li>NHS Group 2 transplants</li> </ul>

### 3. RESULTS

#### REGISTRATION ACTIVITY

- 3.1. There were 9909 new NHS Group 1 liver registrations in the UK in the first ninety months of the scheme. (**Table 1**)
- 3.2. The proportion of elective liver registrations has remained around 89% in the first ninety months post-NLOS. The proportion of adult elective registrations with CLD has returned to 71% in 2024/25 and was 71% in 2017/18. The proportion of HCC registrations (including HCC downstaging) has decreased by three percent to 17%. The proportion of new variant syndrome registrations in 2017/18 and 2024/25 was 9% and 10% respectively. (**Table 3**)
- 3.3. Ninety-two percent of the new adult elective registrations in 2024/25 were for first graft compared with 91% in 2017/2018. (**Table 4**)
- 3.4. The median age of new adult elective registrations was 55 in 2017/2018 and varies between 54 and 56 in the ninety months post-NLOS. (**Table 5**)

#### POST-REGISTRATION OUTCOMES

- 3.5. There were 6238 adult elective registrations in the subset of patients registered in the first 78 months post-NLOS. The proportion of registrations who received a transplant within one year of registration ranged from 59% to 74% across the yearly time periods post NLOS, with 61% of those registered in 2023/24 transplanted within one-year of registration. (**Table 6**)
- 3.6. The proportion of patients who either died on the list or were removed due to condition deterioration in the first year of listing ranged from 6% to 12% in the time periods post NLOS compared to 10% to 11% in the time period prior. In the two-year registration outcome time periods, the proportion of patients who either died on the list or were removed due to condition deterioration ranged from 9% to 14% in the time periods post NLOS compared to 12% to 14% in the time period prior. (**Figures 6 and B4**).

#### LIVER OFFERING

- 3.7. Overall, 6147 DBD and 6691 DCD livers were offered in the first ninety months of the scheme. For DBD donors, the proportion retrieved ranged between 85% and 92% in the 90 months post and 88% in the year prior to NLOS. The equivalent proportion for DCD was 26% to 55% for the 90 months post and 32% in the year prior to NLOS. (**Table 8**).
- 3.8. **Figures 9a and 9b** in the main paper show the number of DBD livers offered during the first ninety months at each stage of the liver offering pathway. Livers offered during COVID are included in **Figure 9a** but excluded at the elective stage of **Figure 9b**. 1018 livers were either accepted and transplanted or declined and not offered on prior to the elective section of the offering pathway.

- 3.9. Of the 4910 DBD livers offered to the elective section that were not offered only to paediatric centres and not offered during the first wave of COVID-19 in 2020, 4419 (90%) were allocated to the elective CLD/HCC pathway while 491 (10%) were randomly allocated to the variant syndrome pathway which is consistent with the percentages used in the probabilistic prioritisation of the elective list.
- 3.10. 2389 livers (not accepted by higher tiers) offered to named elective CLD/HCC were accepted and transplanted while 209 livers offered to the named elective variant syndrome pathway were accepted and transplanted.
- 3.11. 2006 livers declined by all stages were fast-tracked and 777 were accepted and transplanted.
- 3.12. 9915 (35%) of the 28659 offers made in the first 90 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 6788 of the named patient offers involved livers that were ultimately retrieved and transplanted.
- 3.13. The number of named patient offers per donor ranged between 1 and 18 with a median of two named patient offers per donor. The number of named offers per patient ranged between 1 and 34 with a median of two offers per patient.
- 3.14. Sixty nine patients at 7 centres were offered 11 or more livers in the 90 month time period (17 were offered 11 livers, 17 were offered 12 livers, 12 were offered 13 livers, 9 were offered 14 livers, 4 were offered 15 livers, 1 was offered 16, 1 were offered 17, 2 were offered 18 livers, 1 was offered 19 livers, 1 was offered 21, 2 were offered 27, 1 was offered 28 and 1 was offered 34 livers). Ten of the sixty-nine patients offered 11 or more livers in the 90 month time period were on the variant syndrome pathway, 4 were on the HCC pathway and 55 were on the CLD pathway.

#### **TRANSPLANT ACTIVITY**

- 3.15. The proportion of super-urgent transplants performed has increased from prior to NLOS implementation to 2022/23 (11% vs 14% respectively). Between 20 March 2025 and 19 September 2025, 7% of transplants were super-urgent (**Table 14**).
- 3.16. One hundred and forty adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are **included** in the transplant section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients.
- 3.17. For DBD transplants, there was evidence of a statistically significant association between time period and age group ( $p=0.00066$ ), disease group ( $p=0.00098$ ), transplant centre ( $p=0.00100$ ), zonal ( $p<0.0001$ ), type of patient ( $p<0.0001$ ) and blood group compatibility ( $p=0.00290$ ) (**Table 15**).

- 3.18. For DCD transplants, there was evidence of a statistically significant association between time period and age group ( $p=0.03881$ ), disease group ( $p=0.00033$ ), transplant centre ( $p<0.0001$ ) and type of patient ( $p=0.00430$ ). There was no significance for blood group compatibility ( $p=0.08995$ ) or zonal ( $p=0.08482$ ) at the 5% level. (**Table 16**).
- 3.19. There was a statistically significant difference in cold ischaemia time for both adult elective DBD ( $p=0.004$ ) and DCD ( $p<0.001$ ) transplants across the time periods of interest. However, this may be due to the inclusion of periods of machine perfusion which is not currently collected on the liver transplant record form. (**Figures 16-19**)
- 3.20. There was no significant difference in ninety-day DBD and DCD patient survival ( $p$ -value=0.43 and 0.10 respectively). (**Figure 20**). There was no significant difference in ninety-day transplant survival for either DBD and DCD transplants (log-rank  $p$ -value=0.62 and 0.47). (**Figure 21**).
- 3.21. There was no significant difference in one-year DBD and DCD patient survival ( $p$ -value=0.53 and 0.59 respectively). (**Figure 22**). There was no significant difference in one-year transplant survival for either DBD or DCD transplants ( $p$ -value=0.92 and 0.73 respectively). (**Figure 23**).

**Rhiannon Taylor, Maria Jacobs and Rhiannon Wallis**  
**Statistics and Clinical Research**

**October 2025**

**NHS BLOOD AND TRANSPLANT**  
**NATIONAL LIVER OFFERING SCHEME**  
**NINETY MONTH REVIEW**

**1. BACKGROUND**

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity. All full year time periods are 20 March to 19 March.
- 1.2. It should also be noted that this report may not include all data due for the first eighty-four months due to delays in reporting.
- 1.3. The updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in **Figure 9B**.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and NLOS resumed on 9 July 2020.
- 1.5. Birmingham, Royal Free, Kings College and Cambridge temporarily closed for all adult transplants in December 2020/January 2021. Royal Free and Birmingham temporarily transferred some of their clinically urgent patients to other transplant centres who were open. Transplant centres reviewed their transplant lists in January 2021 and formally suspended non-urgent patients. Offering to named clinically urgent patients continued and centres could consider livers for non-urgent patients if declined for all clinically urgent patients.
- 1.6. All transplant centres other than Birmingham formally reactivated all non-urgent CLD and HCC patients on the 6<sup>th</sup> April 2021 while variant syndrome patients and patients at Birmingham were reactivated in late April 2021.

- 1.7. Birmingham closed for all DCD offers in January 2021 with Newcastle and Leeds receiving Birmingham's zonal and linked offers on a rota basis. Birmingham reopened for DCD offers in late April 2021.
- 1.8. The parameter estimates and baseline survivor functions used to calculate the TBS were updated on 4 October 2022. One of the factors (inpatient status) identified as statistically significant in the non-cancer models was set to zero on 23rd May 2023 following discussion at the prior NLOS monitoring committee and LAG Core Group.

## **2. DATA AND METHODS**

### **2.1. REGISTRATION ACTIVITY AND POST-REGISTRATION OUTCOME**

- 2.1.1. Data on 9909 new active/suspended NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 September 2025 were obtained from the UK Transplant Registry on 10 October 2025. Patients registered in Dublin or as NHS Group 2 were excluded as such elective patients would only be offered a liver if all UK transplant centres declined the offer.
- 2.1.2. One and three month registration outcomes were examined, by year, for registrations either between 20 December 2014 and 19 December 2017 (N=2779) or between 20 March 2018 and 19 June 2025 (N=6938).
- 2.1.3. Six month registration outcome was examined for registrations either between 20 September 2014 and 19 September 2017 (N=2781) or between 20 March 2018 and 19 March 2025 (N=6703).
- 2.1.4. One-year registration outcome was examined for registrations either between 20 March 2014 and 19 March 2017 (N=2808) or between 20 March 2018 and 19 September 2024 (N=6238). Two-year registration outcome was examined for a subset registered either between 20 March 2014 and 19 September 2016 (N=1884) or between 20 March 2018 and 19 September 2023 (N=5330).

### **2.2. LIVER OFFERING**

- 2.2.1. Data on 14752 deceased donors (7109 DBD and 7643 DCD) from the UK whose liver was offered for transplantation between 20 March 2017 and 19 September 2025 were obtained from the UK Transplant Registry on 23 October 2025. Intestinal offers were excluded regardless of whether they required a liver or not. The data was split into nine year periods.


### **2.3. TRANSPLANT ACTIVITY AND POST-TRANSPLANT SURVIVAL**

- 2.3.1. Data on 7,640 deceased donor liver transplants (5,743 DBD and 1,897 DCD) performed in the UK between 20 March 2017 and 19 September 2025 were also obtained from the UK Transplant Registry on 10 October 2025. Intestinal transplants involving the liver were included.

### 3. RESULTS

#### 3.1. REGISTRATION ACTIVITY - OVERALL

3.1.1. **Figure 1** shows the number of new NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 September 2025 by quarter and urgency status while **Table 1** compares the twelve months pre the introduction of NLOS and the ninety months post the introduction of NLOS. There was no statistically significant association between the time of registration and registration type (Chi-squared p-value =0.19). It should be noted that there was an increase in the number of paediatric acute liver failure patients in the first two quarters of 2022.



**Table 1****Urgency status by time period for all NHS Group 1 liver registrations in the UK,  
20 March 2017 to 19 September 2025**

Urgency status	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26 <sup>1</sup>	Total
Elective	1035 (89)	1074 (88)	1064 (89)	908 (90)	1115 (91)	1108 (88)	1018 (90)	1022 (90)	518 (91)	8862 (89)
Super-urgent	134 (11)	140 (12)	132 (11)	104 (10)	109 (9)	149 (12)	118 (10)	112 (10)	49 (9)	1047 (11)
<b>Total</b>	<b>1169 (100)</b>	<b>1214 (100)</b>	<b>1196 (100)</b>	<b>1012 (100)</b>	<b>1224 (100)</b>	<b>1257 (100)</b>	<b>1136 (100)</b>	<b>1134 (100)</b>	<b>567 (100)</b>	<b>9909 (100)</b>

<sup>1</sup>20 March 2025 - 19 September 2025

## REGISTRATION ACTIVITY - SUPER-URGENT

3.1.2. **Table 2** compares the twelve months pre the introduction of NLOS and the eighty-four months post the introduction of NLOS by super-urgent category.

The proportion of patients registered as either category 8 (HAT on days 0 to 21) or 9 (Early graft dysfunction on days 0 to 7) was 26% in the year prior and ranged between 18% and 28% in the years post NLOS. **Appendix A** shows the descriptions of each of the categories.

Super-urgent category	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26 <sup>1</sup>	Total
1	2 (1)	3 (2)	4 (3)	3 (3)	5 (5)	5 (3)	3 (3)	0 (0)	0 (0)	25 (2)
2	11 (8)	10 (7)	11 (8)	5 (5)	5 (5)	14 (9)	11 (9)	6 (5)	3 (6)	76 (7)
3	4 (3)	9 (6)	6 (5)	9 (9)	7 (6)	8 (5)	5 (4)	7 (6)	6 (12)	61 (6)
4	2 (1)	2 (1)	2 (2)	3 (3)	4 (4)	1 (1)	8 (7)	4 (4)	3 (6)	29 (3)
5	11 (8)	5 (4)	3 (2)	4 (4)	8 (7)	10 (7)	2 (2)	8 (7)	3 (6)	54 (5)
6	54 (40)	56 (40)	50 (38)	41 (39)	40 (37)	59 (40)	36 (31)	42 (38)	14 (29)	392 (37)
7	6 (4)	3 (2)	9 (7)	8 (8)	10 (9)	10 (7)	10 (8)	5 (4)	0 (0)	61 (6)
8	22 (16)	19 (14)	14 (11)	9 (9)	8 (7)	19 (13)	19 (16)	17 (15)	12 (24)	139 (13)
9	13 (10)	20 (14)	15 (11)	11 (11)	12 (11)	10 (7)	12 (10)	10 (9)	2 (4)	105 (10)
10	4 (3)	4 (3)	6 (5)	0 (0)	0 (0)	1 (1)	2 (2)	1 (1)	1 (2)	19 (2)
20	3 (2)	5 (4)	7 (5)	6 (6)	5 (5)	5 (3)	5 (4)	9 (8)	3 (6)	48 (5)
88	2 (1)	4 (3)	5 (4)	5 (5)	5 (5)	7 (5)	5 (4)	3 (3)	2 (4)	38 (4)
<b>Total</b>	<b>134 (100)</b>	<b>140 (100)</b>	<b>132 (100)</b>	<b>104 (100)</b>	<b>109 (100)</b>	<b>149 (100)</b>	<b>118 (100)</b>	<b>112 (100)</b>	<b>49 (100)</b>	<b>1047 (100)</b>

<sup>1</sup>20 March 2025 - 19 September 2025

### 3.2. REGISTRATION ACTIVITY - ELECTIVE

3.2.1. Table 3 compares the twelve months pre the introduction of NLOS and the ninety months post the introduction of NLOS for NHS Group 1 elective registrations by age and type of patient. There was no statistically significant association between patient age group and time period (Chi-squared p-value =0.40).

**Table 3 Type of elective patient by time period for elective registrations in the UK, 20 March 2017 to 19 September 2025**

Type of patient	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26 <sup>3</sup>	Total
<b>Overall</b>	<b>1035</b>	<b>1074</b>	<b>1064</b>	<b>908</b>	<b>1115</b>	<b>1108</b>	<b>1018</b>	<b>1022</b>	<b>518</b>	<b>8862</b>
<i>Adult elective<sup>1</sup></i>	951 (92)	989 (92)	980 (92)	825 (91)	1038 (93)	1016 (92)	927 (91)	932 (91)	487 (94)	8145 (92)
CLD	674 (71)	720 (73)	738 (75)	635 (77)	786 (76)	741 (73)	656 (71)	659 (71)	352 (72)	5961 (73)
HCC/ HCC downstaging	193 (20)	195 (20)	178 (18)	147 (18)	168 (16)	169 (17)	164 (18)	161 (17)	82 (17)	1457 (18)
Variant syndrome	83 (9)	71 (7)	56 (6)	39 (5)	63 (6)	83 (8)	82 (9)	90 (10)	45 (9)	612 (8)
ACLF	0 (0)	1 (0)	3 (0)	2 (0)	15 (1)	20 (2)	25 (3)	22 (2)	8 (2)	96 (1)
Liver/ cardiothoracic	1 (0)	2 (0)	5 (1)	2 (0)	6 (1)	3 (0)	0 (0)	0 (0)	0 (0)	19 (0)
<i>Paediatric elective<sup>2</sup></i>	84 (8)	85 (8)	84 (8)	83 (9)	77 (7)	92 (8)	91 (9)	90 (9)	31 (6)	717 (8)
Hepatoblastoma/ Prioritised Paediatric	3 (4)	10 (12)	10 (12)	21 (25)	16 (21)	20 (22)	18 (20)	19 (21)	6 (19)	123 (17)
Non hepatoblastoma	81 (96)	74 (87)	74 (88)	62 (75)	59 (77)	72 (78)	73 (80)	71 (79)	25 (81)	591 (82)
Liver/ cardiothoracic	0 (0)	1 (1)	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)	0 (0)	0 (0)	3 (0)

<sup>1</sup> Includes 20 CLD, 1 HCC and 4 Variant syndrome patient aged 17 years or over and weighing 40kg or under (1 in the twelve months prior and 24 in the ninety months post); 20 were dual-listed as small adults (1 in the twelve months prior and 19 in the ninety months post)

<sup>2</sup> Includes 9 hepatoblastoma tier, 120 non hepatoblastoma and 2 liver/cardiothoracic patients aged less than 17 years and weighing 40kg or over (20 in the twelve months prior and 111 in the ninety months post); 106 were dual-listed as large paediatrics (5 in the twelve months prior and 101 in the ninety months post)

<sup>3</sup>20 March 2025 - 19 September 2025

3.2.2. **Table 4** compares the twelve months pre and the ninety months post the introduction of NLOS for each type of adult patient registered over the last 102 months by transplant number. The majority of patients were registered for a first liver transplant and there were no statistically significant associations between whether patient was registered for a first transplant or not and the time period (Chi-squared p-value=0.50).

3.2.3. All but four of the HCC patients were registered for a first graft. Three patients registered for a second graft had a UKELD less than 49 and no current ascites; two of the three patients had no encephalopathy and one had encephalopathy grade 1. One patient registered for a second graft had UKELD greater than 49, no current ascites, and no encephalopathy.

3.2.4. **Table 5** compares the median and interquartile age at registration for the twelve months pre and the ninety months post the introduction of NLOS for each type of adult patient registered over the last 102 months. There were no statistically significant differences in the median recipient age (Kruskal-Wallis p-value $\geq$ 0.34).

**Table 4** Transplant number by time period for adult elective registrations in the UK, 20 March 2017 to 19 September 2025

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26 <sup>5</sup>	Total
<b>CLD<sup>1</sup> (Chi-squared p-value=0.56)</b>										
1 <sup>st</sup> graft	597 (89)	651 (90)	654 (89)	567 (89)	720 (92)	674 (91)	594 (91)	592 (90)	317 (90)	5366 (90)
2 <sup>nd</sup> graft	64 (9)	57 (8)	71 (10)	58 (9)	48 (6)	56 (8)	57 (9)	56 (8)	25 (7)	492 (8)
3 <sup>rd</sup> graft	9 (1)	12 (2)	11 (1)	9 (1)	16 (2)	10 (1)	5 (1)	11 (2)	10 (3)	93 (2)
4 <sup>th</sup> graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	0 (0)	0 (0)	0 (0)	9 (0)
6 <sup>th</sup> graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
<b>HCC/HCC downstaging<sup>2</sup> (Fishers exact p-value=0.96)</b>										
1 <sup>st</sup> graft	192 (99)	194 (99)	178 (100)	147 (100)	168 (100)	168 (99)	164 (100)	160 (99)	82 (100)	1453 (100)
2 <sup>nd</sup> graft	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	4 (0)
<b>Variant syndrome<sup>3</sup> (Chi-squared p-value=0.10)</b>										
1 <sup>st</sup> graft	73 (88)	61 (86)	55 (98)	36 (92)	59 (94)	80 (96)	78 (95)	85 (94)	41 (91)	568 (93)
2 <sup>nd</sup> graft	10 (12)	10 (14)	0 (0)	3 (8)	3 (5)	3 (4)	3 (4)	5 (6)	4 (9)	41 (7)
3 <sup>rd</sup> graft	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	1 (1)	0 (0)	0 (0)	3 (0)
<b>Overall adult elective<sup>4</sup> (Chi-squared p-value=0.50)</b>										
1 <sup>st</sup> graft	863 (91)	909 (92)	895 (91)	754 (91)	967 (93)	945 (93)	861 (93)	858 (92)	448 (92)	7500 (92)
2 <sup>nd</sup> graft	75 (8)	68 (7)	71 (7)	61 (7)	51 (5)	60 (6)	60 (6)	63 (7)	29 (6)	538 (7)
3 <sup>rd</sup> graft	9 (1)	12 (1)	12 (1)	9 (1)	18 (2)	10 (1)	6 (1)	11 (1)	10 (2)	97 (1)
4 <sup>th</sup> graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	0 (0)	0 (0)	0 (0)	9 (0)
6 <sup>th</sup> graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
<b>Total</b>	951 (100)	989 (100)	980 (100)	825 (100)	1038 (100)	1016 (100)	927 (100)	932 (100)	487 (100)	8145 (100)

The p-values above compare first graft and retransplant registrations by time period

<sup>1</sup> One patient dual-listed was registered for a second graft in the twelve months prior whilst seven were registered for a first graft, four for a second graft, three for a third graft and one for a fourth graft in the ninety months post.

<sup>2</sup> Includes HCC downstaging all of whom were registered for first graft.

<sup>3</sup> Three patients dual-listed were registered for first graft and one for a second graft in the ninety months post.

<sup>4</sup> Includes liver and cardiothoracic patients (all of whom were registered for first graft) and hepatoblastoma tier patients (all whom were registered for a first graft except for one registered for a third graft).

<sup>5</sup>20 March 2025 - 19 September 2025

**Table 5 Median (IQR) age by time period for adult elective NHS Group 1 registrations in the UK, 20 March 2017 to 19 September 2025**

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26 <sup>3</sup>	Total
<b>CLD<sup>1</sup> (Kruskal-Wallis p-value=0.39)</b>										
N	674	720	738	635	786	741	656	659	352	<b>5961</b>
Median (IQR)	53 (44 - 61)	54 (44 - 61)	54 (45 - 61)	54 (43 - 61)	54 (43 - 60)	55 (44 - 61)	54 (44 - 61)	55 (43 - 60)	55 (43 - 62)	<b>54 (44 - 61)</b>
Range	17 - 76	17 - 73	17 - 74	17 - 71	17 - 74	17 - 71	17 - 71	17 - 74	17 - 71	<b>17 - 76</b>
<b>HCC/HCC downstaging</b> (Kruskal-Wallis p-value=0.54)										
N	193	195	178	147	168	169	164	161	82	<b>1457</b>
Median (IQR)	60 (55 - 65)	61 (56 - 65)	61 (55 - 66)	60 (56 - 64)	60 (56 - 65.5)	62 (57 - 65)	61 (57 - 65)	62 (57 - 65)	61 (57 - 66)	<b>61 (56 - 65)</b>
Range	20 - 75	21 - 73	21 - 72	19 - 73	43 - 73	37 - 72	27 - 72	34 - 72	38 - 70	<b>19 - 75</b>
<b>Variant syndrome</b> (Kruskal-Wallis p-value=0.65)										
N	83	71	56	39	63	83	82	90	45	<b>612</b>
Median (IQR)	49 (38 - 55)	51 (41 - 58)	48.5 (37.5 - 57.5)	48 (39 - 58)	48 (36 - 56)	48 (37 - 58)	50 (38 - 58)	51.5 (43 - 58)	47 (41 - 55)	<b>49 (39 - 57)</b>
Range	17 - 71	18 - 70	18 - 70	19 - 66	17 - 71	17 - 72	17 - 69	19 - 68	17 - 66	<b>17 - 72</b>
<b>Overall adult elective<sup>2</sup></b> (Kruskal-Wallis p-value=0.34)										
N	951	989	980	825	1038	1016	927	932	487	<b>8145</b>
Median (IQR)	55 (46 - 62)	56 (47 - 62)	55 (47 - 62)	55 (45 - 61)	54.5 (45 - 61)	56 (46 - 62)	55 (45 - 62)	56 (45 - 61)	56 (45 - 62)	<b>55 (46 - 62)</b>
Range	17 - 76	17 - 73	17 - 74	17 - 73	17 - 74	17 - 72	17 - 72	17 - 74	17 - 71	<b>17 - 76</b>

<sup>1</sup> There was one patient dual-listed in the twelve months prior and 19 in the ninety months post

<sup>2</sup> Includes liver and cardiothoracic patients and hepatoblastoma tier patients

<sup>3</sup>20 March 2025 - 19 September 2025

### 3.3. POST-REGISTRATION OUTCOME

3.3.1. **Table 6** shows the one and three-month registration outcome for adult elective NHS Group 1 liver patients registered during the eighty-seven months since the implementation of the NLOS, 20 March 2018 -19 June 2025, along with the prior thirty-six month period, 20 December 2014 – 19 December 2017. Note that the 2025/2026 period covers 3 months due to time to follow-up.

3.3.2. There were 933 adult elective registrations in 2024/2025 and 367 (39%) received a transplant within 3 months of registration. The corresponding three-month transplant rate for patients registered during the twelve months in 2016/2017 is 49%. There were statistically significant differences between the time periods and registration outcome at one month and three month (Chi-squared p-value<0.0001).

3.3.3. **Table 6** also shows the six-month registration outcome for adult elective patients registered during the eighty-four months since the implementation of the NLOS, 20 March 2018 -19 March 2025, along with the prior thirty-six month period, 20 September 2014 – 19 September 2017. There were statistically significant differences between the time periods and registration outcome at six months (Chi-squared p-value<0.0001). In 2024/2025, 488 (52%) of the 933 registrations were transplanted within 6 months compared with 62% in 2016/2017. The proportion of patients who either died on the list or were removed due to condition deterioration within six months was 8% compared with 8% in the 2016/2017 period prior.

3.3.4. **Table 6** also shows the one-year and two-year registration outcomes. The proportion of adults transplanted within twelve months was 61% in 2023/24 and the proportion of adults who either died on the list or were removed due to condition deterioration within twelve months remains around 8%.

Table 6


## Registration outcome for adult elective NHS Group 1 registrations on the UK liver transplant list, 20 March 2014 to 19 June 2025

Registration outcome	2014/15 <sup>1</sup>	2015/16 <sup>1</sup>	2016/17 <sup>1</sup>	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24 <sup>2</sup>	2024/25 <sup>2</sup>	2025/26 <sup>2</sup>
<b>One-month outcome (Chi-squared p-value&lt;0.0001)</b>											
Remained active/suspended	760 (82)	704 (77)	657 (70)	625 (63)	647 (66)	568 (69)	749 (72)	735 (72)	699 (75)	693 (74)	171 (73)
Died/ removed due to CD <sup>3</sup>	25 (3)	19 (2)	21 (2)	14 (1)	10 (1)	20 (2)	16 (2)	23 (2)	11 (1)	18 (2)	
Removed - other reasons	3 (0)	4 (0)	4 (0)	10 (1)	7 (1)	15 (2)	18 (2)	20 (2)	16 (2)	12 (1)	1 (0)
Transplanted	137 (15)	183 (20)	262 (28)	337 (34)	314 (32)	222 (27)	255 (25)	238 (23)	201 (22)	210 (23)	63 (27)
<b>Total</b>	<b>925 (100)</b>	<b>910 (100)</b>	<b>944 (100)</b>	<b>986 (100)</b>	<b>978 (100)</b>	<b>825 (100)</b>	<b>1038 (100)</b>	<b>1016 (100)</b>	<b>927 (100)</b>	<b>933 (100)</b>	<b>235 (100)</b>
<b>Three-month outcome (Chi-squared p-value&lt;0.0001)</b>											
Remained active/suspended	539 (58)	470 (52)	410 (43)	419 (42)	458 (47)	426 (52)	576 (55)	580 (57)	528 (57)	510 (55)	124 (53)
Died/ removed due to CD <sup>3</sup>	56 (6)	44 (5)	55 (6)	32 (3)	27 (3)	39 (5)	34 (3)	42 (4)	29 (3)	41 (4)	3 (1)
Removed - other reasons	11 (1)	9 (1)	12 (1)	18 (2)	15 (2)	23 (3)	22 (2)	25 (2)	22 (2)	15 (2)	3 (1)
Transplanted	319 (34)	387 (43)	467 (49)	517 (52)	478 (49)	337 (41)	406 (39)	369 (36)	348 (38)	367 (39)	105 (45)
<b>Total</b>	<b>925 (100)</b>	<b>910 (100)</b>	<b>944 (100)</b>	<b>986 (100)</b>	<b>978 (100)</b>	<b>825 (100)</b>	<b>1038 (100)</b>	<b>1016 (100)</b>	<b>927 (100)</b>	<b>933 (100)</b>	<b>235 (100)</b>
<b>Six-month outcome (Chi-squared p-value&lt;0.0001)</b>											
Remained active/suspended	367 (39)	312 (33)	242 (27)	275 (28)	319 (33)	288 (35)	419 (40)	426 (42)	378 (41)	370 (40)	
Died/ removed due to CD <sup>3</sup>	81 (9)	86 (9)	68 (8)	44 (4)	48 (5)	73 (9)	62 (6)	67 (7)	52 (6)	51 (5)	
Removed - other reasons	23 (2)	20 (2)	30 (3)	29 (3)	21 (2)	37 (4)	29 (3)	35 (3)	37 (4)	24 (3)	
Transplanted	462 (50)	525 (56)	565 (62)	638 (65)	590 (60)	427 (52)	528 (51)	488 (48)	460 (50)	488 (52)	
<b>Total</b>	<b>933 (100)</b>	<b>943 (100)</b>	<b>905 (100)</b>	<b>986 (100)</b>	<b>978 (100)</b>	<b>825 (100)</b>	<b>1038 (100)</b>	<b>1016 (100)</b>	<b>927 (100)</b>	<b>933 (100)</b>	
<b>One-year outcome (Chi-squared p-value&lt;0.0001)</b>											
Remained active/suspended	181 (19)	168 (18)	132 (14)	153 (16)	187 (19)	167 (20)	280 (27)	252 (25)	238 (26)	112 (24)	
Died/ removed due to CD <sup>3</sup>	109 (11)	97 (10)	101 (11)	64 (6)	76 (8)	95 (12)	89 (9)	96 (9)	75 (8)	39 (8)	
Removed - other reasons	50 (5)	40 (4)	38 (4)	42 (4)	33 (3)	56 (7)	55 (5)	61 (6)	45 (5)	28 (6)	
Transplanted	619 (65)	620 (67)	653 (71)	727 (74)	682 (70)	507 (61)	614 (59)	607 (60)	569 (61)	289 (62)	
<b>Total</b>	<b>959 (100)</b>	<b>925 (100)</b>	<b>924 (100)</b>	<b>986 (100)</b>	<b>978 (100)</b>	<b>825 (100)</b>	<b>1038 (100)</b>	<b>1016 (100)</b>	<b>927 (100)</b>	<b>468 (100)</b>	
<b>Two-year outcome (Chi-squared p-value&lt;0.0001)</b>											
Remained active/suspended	54 (6)	50 (5)		64 (6)	78 (8)	70 (8)	106 (10)	105 (10)	50 (10)		
Died/ removed due to CD <sup>3</sup>	130 (14)	113 (12)		85 (9)	91 (9)	113 (14)	117 (11)	122 (12)	61 (13)		
Removed - other reasons	81 (8)	63 (7)		54 (5)	59 (6)	74 (9)	106 (10)	103 (10)	42 (9)		
Transplanted	694 (72)	699 (76)		783 (79)	750 (77)	568 (69)	709 (68)	686 (68)	334 (69)		
<b>Total</b>	<b>959 (100)</b>	<b>925 (100)</b>		<b>986 (100)</b>	<b>978 (100)</b>	<b>825 (100)</b>	<b>1038 (100)</b>	<b>1016 (100)</b>	<b>487 (100)</b>		


<sup>1</sup>20 December 20XX to 19 December 20XY for one and three-month outcomes, 20 September 20XX to 19 September 20XY for six-month outcome and 20 March 20XX to 19 March 20XY for one-year and two-year outcomes<sup>2</sup>20 March 2025 - June 2025 for one and three-month outcomes, 20 March 2024 to 19 September 2024 for one-year outcomes, 20 March 2023 to 19 September 2023 for two-year outcomes<sup>3</sup> Includes patients removed as registered onto super-urgent list

3.3.5. **Figure 3a** and **Figure 3b** show the one-year and two-year registration outcome by quarter and type of adult elective patient. HCC downstaging registrations are included with HCC registrations. The proportion of CLD patients registered post NLOS and transplanted in the first year post-registration ranged between 55 and 80% compared with 58 and 78% of registrations in the three years prior to NLOS. There was a statistically significant association between one-year transplant rate and time period of registration for CLD patients and HCC/HCC downstaging patients (Chi-squared p-value<0.05). For Variant syndrome patients, 30% of one-year outcomes contained less than 5 patients so the p-value should be observed with caution.

3.3.6. Equivalent charts for three-month and six-month are presented in **Figure B1** and **Figure C1** in **Appendix B** and **Appendix C**.



**Figure 3b Two year registration outcome for active elective liver and liver/kidney patients, by type of patient, 20 March 2014 to 19 September 2023**



3.3.7. **Figure 4a** and **Figure 4b** show the one-year and two-year registration by quarter and age group.

There was a statistically significant association (Chi-squared p-value<0.01) between one-year transplant rate and time period of registration for all age groups except for 17-24 years and two-year transplant rate and time period of registration for all age groups except for 17-24 years and 60+ years. For patients aged 17-24 years, 56% of one-year outcomes contained less than 5 patients so the p-value should be observed with caution. Equivalent charts for three-month and six-month are presented in **Figure B2** and **Figure C2** in **Appendix B** and **Appendix C**.

**Figure 4a One year registration outcome for active elective liver and liver/kidney patients, by age group, 20 March 2014 to 19 September 2024**





Figure 4b Two year registration outcome for active elective liver and liver/kidney patients, by age group, 20 March 2014 to 19 September 2023



3.3.8. **Figure 5a** and **Figure 5b** show the one-year and two-year registration outcome by quarter and whether the patient was registered for a first graft or regraft. The proportion of first graft patients registered post NLOS and transplanted in the first year post-registration ranges between 57 and 79% compared with 62 and 74% of registrations in the three years prior. The proportion of re-graft patients registered post NLOS and transplanted in the first year post-registration ranged between 27 and 71% compared with 50 and 78% of registrations in the three years prior. There was a statistically significant association between one-year transplant rate and time period of registration for patients registered for a first graft but not for regraft patients (Chi-squared p-value <0.01 and 0.14 respectively). There was a statistically significant association between two-year transplant rate and time period of registration for patients registered for a first graft but not for regraft patients (Chi-squared p-value <0.01 and 0.04 respectively). Equivalent charts for three-month and six-month are presented in **Figure B3** and **Figure C3** in **Appendix B** and **Appendix C**.

Figure 5a One year registration outcome for active elective liver and liver/kidney patients, by first transplant or regraft,  
20 March 2014 to 19 September 2024





Figure 5b Two year registration outcome for active elective liver and liver/kidney patients, by first transplant or regraft,  
20 March 2014 to 19 September 2023



3.3.9. **Figure 6a and Figure 6b** shows the one-year and two-year registration outcome by quarter and sex. There was a statistically significant association between transplant rate and time period of registration for male and female patients (Chi-squared p-value <0.01). Equivalent charts for three-month and six-month are presented in **Figure B4** and **Figure C4** in **Appendix B** and **Appendix C** and show consistent results with the one-year outcome chart.

Figure 6a One year registration outcome for active elective liver and liver/kidney patients, by sex,  
20 March 2014 to 19 September 2024







Figure 6b Two year registration outcome for active elective liver and liver/kidney patients, by sex,  
20 March 2014 to 19 September 2023



3.3.10. **Figure 7a and Figure 7b** shows the one-year and two-year registration outcome by quarter. The mortality rate in the first year ranged between 5% and 13% in the quarters since the introduction of NLOS compared with between 9% and 15% in the quarters prior. Equivalent charts for three-month and six-month outcome are presented in **Figure B5** and **Figure C5** in **Appendix B** and **Appendix C**.



3.3.11. One hundred and twelve patients listed for a regraft, either on the list on 20 March 2018 or registered during the ninety months post NLOS, were removed from the transplant list (regardless of reason). **Table 7** shows the reasons for removal from the transplant list for each of the 112 patients.

**Table 7 Reasons for removal for 112 regraft patients removed from the transplant list**

Patient number	Centre	Month removed	Time from previous tx to re-registration	Active time on the list	Reason for removal	Other reasons given
1	6	March 2018	1940	2562	Condition deteriorated	Deterioration of Hocum therefore not fit for OLTX At patient's request
2	6	April 2018	1245	2	Other	
3	5	May 2018	527	212	Condition deteriorated	
4	5	May 2018	1178	266	Condition improved	
5	6	July 2018	1106	247	Condition improved	
6	5	August 2018	480	596	Condition deteriorated	
7	6	September 2018	1220	55	Condition deteriorated	
8	6	December 2018	2799	24	Condition deteriorated	
9	3	February 2019	1903	337	Condition deteriorated	Patient has developed lung cancer Has extra hepatic collections, needs addressing Further investigations required for anaemia and cardiac function
10	4	March 2019	2220	392	Condition improved	
11	5	April 2019	2736	6	Condition deteriorated	Patient has deteriorated and is no longer a transplant candidate.
12	6	June 2019	2564	74	Condition improved	
13	3	September 2019	158	150	Condition deteriorated	HCC in nodes outsides liver
14	5	October 2019	3351	66	Condition deteriorated	Patient has developed multi-organ failure, rising lactate in the context of sepsis.
15	6	November 2019	5275	879	Condition deteriorated	Pt requires full assessment for retransplant now, after a long period of suspension on the waiting list since Aug 2018. Deemed medically too high risk to receive a transplant
16	3	December 2019	49	13	Condition improved	Clinically improving. No longer has an indication for transplant
17	7	January 2020	179	117	Condition deteriorated	
18	5	February 2020	7655	164	Condition deteriorated	HCC metastases super urgent request sent through via National appeal.
19	5	February 2020	808	604	Condition deteriorated	
20	4	February 2020	103	30	Condition improved	
21	3	February 2020	645	93	Condition improved	
22	1	March 2020	6929	10	Condition deteriorated	
23	5	July 2020	2907	609	Condition deteriorated	
24	6	July 2020	5537	764	Other	Patient now for palliative care in their local hospital
25	3	September 2020	56	1	Condition improved	
26	5	March 2021	11009	927	Condition deteriorated	
27	2	April 2021	62	15	Other	Moved to su waiting list
28	6	April 2021	710	3	Condition improved	
29	6	May 2021	5498	74	Condition deteriorated	
30	7	May 2021	10069	654	Condition deteriorated	Patient pyrexial; patient died
31	4	May 2021	26	0	Registered onto the super-urgent list	
32	4	June 2021	545	381	Condition deteriorated	Admitted to ITU. Aim to get patient off ITU and to discharge with palliative care
33	5	June 2021	6249	84	Condition improved	Clinical condition improved since listing
34	6	August 2021	128	11	Condition deteriorated	Patient went for transplant found to have malignancy therefore abandoned
35	6	October 2021	198	739	Condition improved	
36	7	October 2021	168	103	Condition deteriorated	Patient too sick for liver transplant
37	2	October 2021	468	82	Patient/non-compliant	Following MDT - majority of the team do not support transplant due to concerns with compliance
38	5	October 2021	320	90	Condition deteriorated	
39	5	November 2021	1642	62	Condition deteriorated	Deteriorated and patient not keen on transplant
40	3	November 2021	1617	6	Condition deteriorated	New PLTD diagnosis
41	5	November 2021	1866	1256	Condition deteriorated	Patient transferred and under assessment at new centre
42	2	November 2021	6606	42	Condition improved	
43	6	December 2021	2649	457	Other	Drinking alcohol whilst on the waiting list

44	1	December 2021	53	4	Condition deteriorated	
45	6	January 2022	876	113	Condition improved	
46	6	March 2022	5352	32	Condition deteriorated	End of life care. Frailty. Refractory leg abscess. MOF.
47	2	April 2022	1463	185	Patient/non-compliant	
48	6	April 2022	1404	241	Condition improved	
49	4	May 2022	245	283	Condition improved	No indication for transplant-improved
50	5	June 2022	5910	698	Condition deteriorated	
51	3	July 2022	5802	65	Condition improved	
52	4	September 2022	513	448	Patient/non-compliant	Drinking alcohol whilst on the waiting list.
53	1	October 2022	271	58	Condition deteriorated	
54	6	October 2022	1014	396	Other	Dwindling indication
55	3	November 2022	3707	481	Condition deteriorated	
56	5	November 2022	9577	481	Patient/non-compliant	
57	1	December 2022	47	156	Condition improved	No longer meets listing criteria
58	5	January 2023	6133	1069	Condition deteriorated	
59	6	January 2023	1620	187	Condition improved	
60	6	February 2023	661	40	Condition improved	
61	6	February 2023	2297	30	Condition improved	
62	6	February 2023	748	540	Condition improved	
63	2	March 2023	1585	76	Patient/Non-compliant	Non-compliant
64	3	April 2023	2395	699	Condition deteriorated	
65	7	April 2023	6700	1817	Other (please specify)	Patient stable, does not require transplant at this time.
66	6	April 2023	170	211	Condition improved	
67	3	May 2023	1624	4	Condition deteriorated/patient unfit/medical contra-indication	
68	2	May 2023	2394	413	Other (please specify)	No further episodes of cholangitis since removal of phytobezoar
69	5	September 2023	2000	30	Condition deteriorated	Nutritionally depleted and severely deconditioned.
70	6	September 2023	9232	808	Condition deteriorated	
71	7	September 2023	9211	118	Registered onto Super-Urgent list	
72	5	September 2023	308	339	Condition improved	
73	4	October 2023	994	162	Condition improved	
74	3	October 2023	6783	804	Condition deteriorated	
75	6	October 2023	10617	1752	Condition deteriorated	
76	1	November 2023	280	494	Condition improved	
77	5	December 2023	1164	821	Condition deteriorated	De-list on co-morbidity profile.
78	3	December 2023	2832	430	Condition improved	
79	5	December 2023	1246	4	Patient/Non-compliant	
80	5	January 2024	1463	429	Patient/Non-compliant	
81	6	January 2024	147	39	Condition deteriorated	
82	5	February 2024	785	1785	Condition deteriorated	
83	3	February 2024	21	16	Registered onto Super-Urgent list	
84	5	March 2024	5299	336	Condition deteriorated	HCC outside criteria
85	6	March 2024	111	1018	Condition improved	Too well - recolltarised
86	3	March 2024	2408	1126	Condition improved	
87	6	March 2024	2797	439	Condition deteriorated	Now too high risk
88	5	May 2024	296	48	Condition improved	Clinical improvement
89	6	June 2024	3313	216	Condition deteriorated	Palliative
90	6	July 2024	2585	419	Condition deteriorated	
91	2	July 2024	680	7	Condition deteriorated	Diagnosed with oesophageal cancer
92	5	September 2024	4968	413	Condition deteriorated	Active rectal cancer
93	4	September 2024	48	37	Condition deteriorated	Patient deteriorated
94	5	September 2024	291	606	Condition improved	No indication
95	5	October 2024	1361	937	Condition deteriorated	Deteriorated
96	4	October 2024	2573	11	Other (please specify)	Patient has left the country
97	6	October 2024	7983	906	Condition improved	
98	3	November 2024	112	198	Condition improved	
99	5	November 2024	354	1063	Patient/parent request	Clinical improvement
100	5	January 2025	4522	1080	Patient/non-compliant	Did not attend appointment and scans
101	3	March 2025	10310	334	Condition deteriorated/patient unfit/medical contra-indication	Sepsis
102	6	May 2025	972	7	Other (please specify)	To be super urgent listed

103	2	May 2025	9386	22	Condition improved	
104	5	June 2025	935	551	Condition improved	
105	6	June 2025	2235	470	Condition improved	
106	2	June 2025	4797	591	Patient unfit	MDT discussion, not fit for re-graft
107	4	July 2025	1561	527	Patient unfit	
108	6	July 2025	365	365	Condition improved	No indication due to improvement
109	2	August 2025	58	17	Patient unfit	
					Condition	
110	6	September 2025	712	495	deteriorated/patient unfit/medical contra-indication	
111	3	September 2025	85	53	Condition improved	
112	6	September 2025	2469	200	Patient/non-compliant	Poor engagement

### 3.4. LIVER OFFERING

3.4.1. **Table 8A** and **Table 8B** shows the overall UK DBD and DCD liver offering outcome between 20 March 2017 and 19 September 2025, by donor type and time period. 6147 DBD and 6691 DCD livers were offered for transplantation in the first ninety months of the scheme. Of the DBD livers offered, 5411 (88%) were retrieved for the purposes of transplantation and 4634 (86%) were transplanted (all but 30 were transplanted in the UK). The proportion of DBD livers offered and retrieved is very similar to the percentage for the 12 months prior to the introduction of the new scheme. **Table 8A** and **Table 8B** also shows the liver offering outcome for donors where at least one solid organ was retrieved for the purposes of transplantation.

3.4.2. **Table 9A to 9E** shows, separately, the reasons for not offering, not retrieving and not transplanting livers by donor type and time period. The number in brackets are the corresponding values for solid organ donors where at least one organ was retrieved for the purposes of transplantation.

**Table 8A DBD donor liver offering outcome, 20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
<b>1A. ALL DONORS</b>									
Number donors	1067	1072	1070	875	882	830	860	728	354
Liver not offered for donation	105	72	69	84	80	59	68	62	30
Liver offered for donation	962	1000	1001	791	802	771	792	666	324
Liver not retrieved (% offered)	118 (12%)	143 (14%)	134 (13%)	117 (15%)	88 (11%)	75 (10%)	96 (12%)	58 (9%)	25 (8%)
Liver retrieved (% offered)	844 (88%)	857 (86%)	867 (87%)	674 (85%)	714 (89%)	696 (90%)	696 (88%)	608 (91%)	299 (92%)
Livers transplanted overseas (% retrieved)	4 (0%)	9 (1%)	3 (0%)	2 (0%)	6 (1%)	2 (0%)	5 (1%)	2 (0%)	1 (0%)
Livers transplanted in the UK (% retrieved)	765 (91%)	754 (88%)	735 (85%)	580 (86%)	604 (85%)	599 (86%)	564 (81%)	516 (85%)	252 (84%)
Liver not transplanted (% retrieved)	75 (9%)	94 (11%)	129 (15%)	92 (14%)	104 (15%)	95 (14%)	127 (18%)	90 (15%)	46 (15%)
Used for research (% not transplanted)	44 (59%)	52 (55%)	70 (54%)	22 (24%)	47 (45%)	41 (43%)	44 (35%)	42 (47%)	20 (43%)
<b>2. SOLID ORGAN DONORS</b>									
Number donors	949	965	965	752	789	770	778	672	327
Liver not offered for donation	45	28	23	23	27	24	26	24	14
Liver offered for donation	904	937	942	729	762	746	752	648	313
Liver not retrieved (% offered)	60 (7%)	80 (9%)	75 (8%)	55 (8%)	48 (6%)	50 (7%)	56 (7%)	40 (6%)	14 (4%)
Liver retrieved (% offered)	844 (93%)	857 (91%)	867 (92%)	674 (92%)	714 (94%)	696 (93%)	696 (93%)	608 (94%)	299 (96%)
Livers transplanted overseas (% retrieved)	4 (0%)	9 (1%)	3 (0%)	2 (0%)	6 (1%)	2 (0%)	5 (1%)	2 (0%)	1 (0%)
Livers transplanted in the UK (% retrieved)	765 (91%)	754 (88%)	735 (85%)	580 (86%)	604 (85%)	599 (86%)	564 (81%)	516 (85%)	252 (84%)
Liver not transplanted (% retrieved)	75 (9%)	94 (11%)	129 (15%)	92 (14%)	104 (15%)	95 (14%)	127 (18%)	90 (15%)	46 (15%)
Used for research (% not transplanted)	44 (59%)	52 (55%)	70 (54%)	22 (24%)	47 (45%)	41 (43%)	44 (35%)	42 (47%)	20 (43%)

**Table 8B DCD donor liver offering outcome, 20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
<b>1A. ALL DONORS</b>									
Number donors	1164	1224	1275	717	1033	1059	1139	1065	585
Liver not offered for donation	212	225	237	140	187	163	185	181	88
Liver offered for donation	952	999	1038	577	846	896	954	884	497
Liver not retrieved (% offered)	652 (68%)	741 (74%)	751 (72%)	407 (71%)	533 (63%)	529 (59%)	546 (57%)	449 (51%)	223 (45%)
Liver retrieved (% offered)	300 (32%)	258 (26%)	287 (28%)	170 (29%)	313 (37%)	367 (41%)	408 (43%)	435 (49%)	274 (55%)
Livers transplanted overseas (% retrieved)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Livers transplanted in the UK (% retrieved)	198 (66%)	191 (74%)	176 (61%)	114 (67%)	195 (62%)	243 (66%)	262 (64%)	312 (72%)	194 (71%)
Liver not transplanted (% retrieved)	102 (34%)	67 (26%)	111 (39%)	56 (33%)	118 (38%)	124 (34%)	146 (36%)	123 (28%)	80 (29%)
Used for research (% not transplanted)	63 (62%)	39 (58%)	63 (57%)	23 (41%)	54 (46%)	57 (46%)	58 (40%)	52 (42%)	38 (48%)
<b>2. SOLID ORGAN DONORS</b>									
Number donors	616	643	655	388	623	653	732	724	407
Liver not offered for donation	44	51	41	31	51	40	47	51	31
Liver offered for donation	572	592	614	357	572	613	685	673	376
Liver not retrieved (% offered)	272 (48%)	334 (56%)	327 (53%)	187 (52%)	259 (45%)	246 (40%)	277 (40%)	238 (35%)	102 (27%)
Liver retrieved (% offered)	300 (52%)	258 (44%)	287 (47%)	170 (48%)	313 (55%)	367 (60%)	408 (60%)	435 (65%)	274 (73%)
Livers transplanted overseas (% retrieved)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Livers transplanted in the UK (% retrieved)	198 (66%)	191 (74%)	176 (61%)	114 (67%)	195 (62%)	243 (66%)	262 (64%)	312 (72%)	194 (71%)
Liver not transplanted (% retrieved)	102 (34%)	67 (26%)	111 (39%)	56 (33%)	118 (38%)	124 (34%)	146 (36%)	123 (28%)	80 (29%)
Used for research (% not transplanted)	63 (62%)	39 (58%)	63 (57%)	23 (41%)	54 (46%)	57 (46%)	58 (40%)	52 (42%)	38 (48%)

**Table 9A Reasons for non-offering of DBD livers (solid organ donors),  
20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
Family permission not sought	1 (1)	0 (0)	0 (0)	1 (1)	2 (2)	1 (0)	1 (0)	1 (1)	0 (0)
Family permission refused	20 (11)	10 (3)	8 (5)	3 (3)	7 (3)	2 (2)	9 (4)	6 (3)	5 (4)
Permission refused by coroner	18 (9)	7 (4)	0 (0)	5 (3)	7 (4)	6 (4)	5 (2)	4 (2)	2 (2)
Offer withdrawn	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)
Donor unsuitable - age	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Donor unsuitable - past history	30 (20)	17 (14)	21 (16)	19 (13)	18 (15)	14 (14)	20 (17)	15 (12)	7 (7)
Donor unstable	1 (0)	1 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Poor function	1 (0)	7 (6)	2 (2)	2 (2)	3 (2)	1 (1)	3 (2)	0 (0)	0 (0)
Donor unsuitable - virology	4 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Other, please specify	8 (1)	2 (1)	3 (0)	7 (1)	2 (1)	3 (3)	1 (1)	0 (0)	0 (0)
Poor function - initial assessment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (3)	1 (1)
Not reported	21 (1)	28 (0)	35 (0)	46 (0)	41 (0)	32 (.)	28 (0)	27 (0)	13 (0)
Other, please specify - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (0)
<b>Total not offered</b>	<b>105 (45)</b>	<b>72 (28)</b>	<b>69 (23)</b>	<b>84 (23)</b>	<b>80 (27)</b>	<b>59 (24)</b>	<b>68 (26)</b>	<b>62 (24)</b>	<b>30 (14)</b>

**Table 9B Reasons for non-retrieval of DBD livers (solid organ donors),  
20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
Donor unsuitable - cause of death	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Donor unsuitable - age	5 (3)	5 (4)	2 (2)	1 (0)	2 (0)	1 (0)	2 (0)	0 (0)	0 (0)
Donor unsuitable - past history	44 (21)	49 (25)	48 (28)	50 (30)	40 (21)	26 (19)	32 (18)	22 (15)	8 (3)
Donor unstable	2 (0)	2 (1)	0 (0)	0 (0)	0 (0)	1 (0)	3 (0)	0 (0)	0 (0)
Donor unsuitable - size	1 (0)	9 (4)	3 (3)	2 (0)	3 (3)	1 (1)	4 (4)	2 (2)	0 (0)
Donor arrested	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	3 (0)	1 (0)	1 (0)
No suitable recipients	6 (4)	8 (4)	10 (5)	4 (2)	7 (3)	6 (6)	5 (5)	2 (2)	2 (1)
Centre already transplanting	1 (1)	0 (0)	0 (0)	2 (0)	0 (0)	1 (0)	1 (1)	0 (0)	0 (0)
Poor function	17 (11)	16 (12)	16 (9)	16 (8)	7 (6)	6 (3)	6 (5)	0 (0)	0 (0)
Infection	0 (0)	3 (0)	1 (0)	1 (0)	0 (0)	1 (0)	0 (0)	2 (1)	0 (0)
Donor unsuitable - Tumour, please specify	2 (0)	0 (0)	3 (0)	1 (0)	2 (0)	1 (0)	1 (0)	0 (0)	0 (0)
Anatomical anomaly, please specify	0 (0)	0 (0)	1 (1)	2 (1)	4 (3)	4 (4)	9 (7)	3 (0)	2 (2)
Other disease, please specify	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HLA/ABO type	2 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)
Contamination - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	0 (0)
No beds	0 (0)	0 (0)	1 (1)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
No response to fast track/group offer	1 (1)	2 (2)	1 (1)	1 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Steatosis (Fatty organ) - organ unsuitable	10 (8)	14 (12)	12 (10)	7 (5)	7 (7)	10 (8)	8 (6)	5 (4)	6 (4)
Donor unsuitable - virology	9 (0)	7 (1)	13 (3)	1 (0)	1 (0)	3 (1)	3 (1)	1 (0)	1 (0)
Organ/tissue unsuitable for transplant	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	3 (1)	2 (2)	0 (0)	0 (0)
Other, please specify	17 (8)	27 (14)	21 (10)	22 (4)	12 (2)	11 (7)	8 (3)	0 (0)	0 (0)
Fibrosis	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)
Organ damage (retrieval injury), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Organ damage (pre-mortem), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)
Poor function - initial assessment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	7 (6)	1 (1)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Organ failed viability assessment, please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Renal tumour, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)
Other, please specify - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	1 (0)
Other, please specify - centre reason	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	5 (4)	1 (1)
<b>Total not retrieved</b>	<b>118 (60)</b>	<b>143 (80)</b>	<b>134 (75)</b>	<b>117 (55)</b>	<b>88 (48)</b>	<b>75 (50)</b>	<b>96 (56)</b>	<b>58 (40)</b>	<b>25 (14)</b>

**Table 9C Reasons DBD livers (solid organ donors) were retrieved but not transplanted, 20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
Steatosis (Fatty organ)	8 (8)	14 (14)	16 (16)	30 (30)	30 (30)	30 (30)	42 (42)	17 (17)	14 (14)
Anatomical anomaly	3 (3)	4 (4)	3 (3)	10 (10)	20 (20)	9 (9)	20 (20)	11 (11)	7 (7)
Poor function	0 (0)	1 (1)	1 (1)	4 (4)	10 (10)	9 (9)	11 (11)	0 (0)	0 (0)
Ischaemia time too long - cold	4 (4)	4 (4)	3 (3)	5 (5)	4 (4)	1 (1)	2 (2)	3 (3)	0 (0)
Donor unsuitable - past history	0 (0)	0 (0)	1 (1)	6 (6)	3 (3)	5 (5)	7 (7)	0 (0)	4 (4)
Donor unsuitable - size	1 (1)	0 (0)	1 (1)	1 (1)	7 (7)	3 (3)	5 (5)	6 (6)	1 (1)
Organ damaged	0 (0)	0 (0)	3 (3)	4 (4)	3 (3)	2 (2)	7 (7)	0 (0)	0 (0)
Donor unsuitable - Tumour	3 (3)	0 (0)	2 (2)	0 (0)	2 (2)	2 (2)	2 (2)	0 (0)	1 (1)
Poor function following machine perfusion	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (6)	3 (3)
Poor perfusion	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	2 (2)	1 (1)	3 (3)	0 (0)
Recipient unfit	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	3 (3)	0 (0)
Fibrosis	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
No suitable recipients	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Recipient died	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Recipient unavailable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Recipient refused	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)	1 (1)	0 (0)
No response to fast track	3 (3)	2 (2)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Organ unsuitable for transplant	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Organ damage (retrieval injury)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	3 (3)	2 (2)
Organ damage (at transplant centre), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Organ damage (pre-mortem)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Renal tumour	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Other, please specify	11 (11)	19 (19)	32 (32)	24 (24)	18 (18)	22 (22)	11 (11)	0 (0)	0 (0)
Other - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	3 (3)	0 (0)
Other - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (4)	6 (6)	7 (7)
Other - recipient unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Other - research/disposed of	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (7)	23 (23)	3 (3)
Used for research after declined by centres	42 (42)	49 (49)	64 (64)	5 (5)	5 (5)	5 (5)	1 (1)	0 (0)	0 (0)
<b>TOTAL RETRIEVED, NOT TRANSPLANTED</b>	<b>75 (75)</b>	<b>94 (94)</b>	<b>129 (129)</b>	<b>92 (92)</b>	<b>104 (104)</b>	<b>95 (95)</b>	<b>127 (127)</b>	<b>90 (90)</b>	<b>46 (46)</b>

**Table 9D Reasons DCD livers (solid organ donors) were not offered, 20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
Family permission not sought	2 (2)	2 (2)	1 (1)	0 (0)	1 (0)	2 (1)	2 (2)	3 (3)	2 (2)
Family permission refused	26 (6)	18 (6)	3 (1)	9 (2)	9 (4)	14 (3)	12 (0)	6 (0)	6 (3)
Permission refused by coroner	5 (0)	9 (5)	10 (3)	4 (3)	8 (4)	6 (3)	9 (4)	9 (4)	6 (2)
Donor unsuitable - age	8 (4)	5 (2)	10 (6)	26 (11)	7 (5)	5 (3)	11 (7)	2 (1)	2 (1)
Donor unsuitable - past history	51 (23)	54 (27)	48 (18)	27 (12)	52 (29)	39 (23)	48 (25)	49 (32)	25 (20)
Donor recovered	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Donor unstable	4 (1)	1 (1)	2 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Donor unsuitable - size	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	3 (3)	3 (3)	1 (1)	0 (0)
Donor arrested	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	1 (0)
No suitable recipients	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (1)	0 (0)
Centre already transplanting	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)
Poor function	13 (5)	16 (7)	12 (6)	2 (1)	10 (6)	5 (4)	8 (1)	0 (0)	0 (0)
Infection	4 (0)	1 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	0 (0)	0 (0)
Other disease, please specify	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HLA/ABO type	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Organ damaged	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Ischaemia time too long - warm	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Ischaemia time too long - cold	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)
No response to fast track/group offer	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)
Donor unsuitable - virology	1 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Other, please specify	26 (2)	18 (0)	26 (4)	7 (1)	12 (2)	6 (0)	6 (1)	0 (0)	0 (0)
Prolonged time to asystole	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Organ damage (pre-mortem), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Poor function - initial assessment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	9 (5)	3 (2)
Not reported	72 (1)	98 (0)	122 (0)	65 (1)	87 (0)	81 (0)	76 (0)	91 (0)	41 (0)
Other, please specify - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	1 (0)
Other, please specify - logistic issues	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (1)	1 (1)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)
<b>Total not offered</b>	<b>212 (44)</b>	<b>225 (51)</b>	<b>237 (41)</b>	<b>140 (31)</b>	<b>187 (51)</b>	<b>163 (40)</b>	<b>185 (47)</b>	<b>181 (51)</b>	<b>88 (31)</b>

**Table 9E Reasons for non-retrieval of DCD livers (solid organ donors),  
20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
Donor unsuitable - cause of death	0 (0)	0 (0)	0 (0)	1 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Donor unsuitable - age	142 (55)	198 (93)	181 (82)	59 (28)	133 (65)	113 (64)	70 (33)	64 (39)	25 (18)
Donor past history	141 (75)	186 (99)	176 (89)	117 (64)	154 (91)	144 (84)	173 (100)	135 (93)	61 (37)
Donor recovered	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Donor unstable	2 (0)	3 (0)	0 (0)	0 (0)	1 (0)	5 (0)	2 (1)	0 (0)	0 (0)
Donor unsuitable - size	17 (12)	21 (15)	26 (18)	13 (8)	15 (9)	17 (14)	19 (13)	7 (5)	9 (5)
Donor arrested	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	2 (0)	0 (0)	4 (0)	1 (0)
No suitable recipients	26 (14)	30 (18)	41 (18)	27 (16)	24 (15)	14 (8)	35 (24)	20 (12)	8 (5)
No time	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Centre already transplanting	1 (1)	0 (0)	8 (5)	5 (2)	3 (1)	7 (4)	4 (2)	3 (2)	1 (1)
Poor function	49 (32)	49 (32)	51 (31)	30 (17)	32 (24)	28 (15)	45 (31)	0 (0)	0 (0)
Infection	2 (0)	3 (3)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	2 (1)	0 (0)
Donor unsuitable - Tumour, Anatomical anomaly	1 (0)	0 (0)	1 (0)	1 (0)	0 (0)	0 (0)	2 (0)	3 (1)	0 (0)
Poor perfusion	0 (0)	0 (0)	1 (1)	0 (0)	4 (4)	2 (2)	4 (4)	3 (2)	4 (2)
Other disease	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)
HLA/ABO type	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	1 (1)	2 (1)	1 (1)	2 (2)	1 (1)	3 (3)	2 (2)	0 (0)	0 (0)
Contamination	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (0)
Ischaemia time too long - warm	0 (0)	1 (0)	2 (0)	13 (10)	22 (9)	32 (12)	30 (18)	13 (7)	9 (4)
Ischaemia time too long - cold	0 (0)	1 (0)	0 (0)	3 (3)	4 (3)	1 (0)	2 (2)	2 (2)	1 (1)
No beds	0 (0)	1 (1)	0 (0)	1 (0)	5 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Transport difficulties	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
No response to fast track	11 (2)	4 (1)	6 (4)	11 (5)	3 (2)	1 (0)	3 (2)	3 (2)	0 (0)
Steatosis (Fatty organ)	12 (10)	7 (7)	9 (6)	1 (1)	2 (2)	11 (10)	6 (5)	8 (8)	6 (6)
Donor unsuitable - virology	8 (0)	10 (0)	13 (3)	4 (1)	6 (1)	0 (0)	3 (1)	3 (0)	1 (0)
Organ unsuitable for tx	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	1 (1)	3 (2)	0 (0)	0 (0)
Other, please specify	237 (69)	222 (64)	234 (69)	117 (28)	117 (24)	146 (28)	105 (27)	0 (0)	0 (0)
Fibrosis	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)	1 (1)	1 (1)
Prolonged time to asystole	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	29 (3)	125 (24)	71 (8)
Organ damage (retrieval injury)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)
Organ damage (pre-mortem)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Poor function - initial assess	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	20 (15)	9 (6)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	8 (8)	4 (4)
No suitable recipients due to reduced patient list	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Other - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	7 (2)	3 (0)
Other - logistic issues	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	6 (5)	2 (2)
Other - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	6 (6)	4 (2)
Other - recipient unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
<b>TOTAL NOT RETRIEVED</b>	<b>652</b>	<b>741</b>	<b>751</b>	<b>407</b>	<b>533</b>	<b>529</b>	<b>546 (277)</b>	<b>449 (238)</b>	<b>223 (102)</b>

**Table 9F Reasons DCD livers (solid organ donors) retrieved but not transplanted, 20 March 2017 to 19 September 2025, as at 23 October 2025**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	Mar-Sep 25
<b>REASONS RETRIEVED BUT NOT TRANSPLANTED</b>									
<b>Donor unsuitable - age</b>									
Donor past history	0 (0)	0 (0)	1 (1)	2 (2)	2 (2)	4 (4)	0 (0)	6 (6)	1 (1)
Donor unsuitable - size	0 (0)	0 (0)	1 (1)	1 (1)	3 (3)	6 (6)	4 (4)	12 (12)	7 (7)
No suitable recipients	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Poor function	0 (0)	0 (0)	1 (1)	1 (1)	5 (5)	15 (15)	19 (19)	22 (22)	0 (0)
Infection	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)
Donor unsuitable - Tumour	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	2 (2)
Anatomical anomaly	1 (1)	0 (0)	5 (5)	6 (6)	10 (10)	11 (11)	14 (14)	12 (12)	8 (8)
Poor perfusion	2 (2)	2 (2)	2 (2)	1 (1)	2 (2)	1 (1)	5 (5)	6 (6)	6 (6)
HLA/ABO type	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	1 (1)	0 (0)	3 (3)	2 (2)	3 (3)	6 (6)	5 (5)	0 (0)	0 (0)
Contamination - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)
Ischaemia time too long - warm	4 (4)	3 (3)	3 (3)	4 (4)	6 (6)	3 (3)	12 (12)	3 (3)	3 (3)
Ischaemia time too long - cold	3 (3)	6 (6)	4 (4)	2 (2)	7 (7)	5 (5)	10 (10)	3 (3)	3 (3)
Recipient unfit	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Recipient died	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Recipient unavailable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Taken for hepatocytes	0 (0)	0 (0)	2 (2)	2 (2)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
No response to fast track	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Used for research after declined by centres	60 (60)	36 (36)	57 (57)	5 (5)	7 (7)	2 (2)	2 (2)	0 (0)	0 (0)
Steatosis (Fatty organ)	7 (7)	5 (5)	5 (5)	4 (4)	22 (22)	33 (33)	14 (14)	28 (28)	21 (21)
Organ unsuitable for tx	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)
Other, please specify	22 (22)	12 (12)	25 (25)	18 (18)	32 (32)	29 (29)	21 (21)	0 (0)	0 (0)
Fibrosis	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	3 (3)	1 (1)
Organ damage (retrieval injury)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	5 (5)
Organ damage (at tx centre)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Organ damage (pre-mortem)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Poor function - initial assess	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (7)	1 (1)
Renal tumour	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (2)	0 (0)
Poor function following machine perfusion	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	15 (15)	15 (15)
Other - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Other - logistic issues	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Other - centre reason	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Other - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	9 (9)	5 (5)
Other - organ unsuitable for named recipient	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Other, please specify - research/disposed of	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	15 (15)	3 (3)
<b>TOTAL RETRIEVED, NOT TRANSPLANTED</b>	<b>102 (102)</b>	<b>67 (67)</b>	<b>111 (111)</b>	<b>56 (56)</b>	<b>118 (118)</b>	<b>124 (124)</b>	<b>146 (146)</b>	<b>123 (123)</b>	<b>80 (80)</b>

3.4.3. **Figure 8** shows the DBD liver offering outcome for all livers offered regardless of whether any solid organs were retrieved for the purposes of transplantation. **Figure 8** shows that 276 livers were offered during the first quarter of NLOS which was the second highest number of livers offered during the 90 month period.

3.4.4. The percentage of organs retrieved and transplanted per quarter ranged from 77% to 82% in the year prior and 67% to 82% in the 90 months post the introduction of NLOS. The percentage of livers retrieved and used for research ranged between 3% and 6% in the year prior and 1% to 10% for the 90 months post the introduction of NLOS.

3.4.5. **Figure 8A** shows the equivalent information for all solid organ donors where the liver was offered for transplantation and at least one organ (not necessarily the liver) was retrieved for the purposes of transplantation.

**Figure 8 DBD donor liver offering outcome regardless of whether the donor was a solid organ donor, by quarter and offering outcome, 20 March 2017 to 19 September 2025**





Figure 8A DBD donor liver offering outcome for solid organ donors, by quarter and offering outcome,



3.4.6. **Figure 9a** show the number of livers offered during the first 90 months of the new scheme at each stage of the liver offering pathway up to and including the liver and cardiothoracic section. Livers offered during COVID are included in **Figure 9a** but excluded at the elective stage of **Figure 9b**. 76 of the 6147 donors did not meet the DBD criteria at the start of the offering process. Forty-nine of the 76 were only ever offered as DCD and 43 were retrieved and transplanted. These livers are hence excluded from the offering pathway.

3.4.7. Livers from 725 donors meeting the DBD criteria were accepted and transplanted into super-urgent patients (including 29 super-urgent patients in Dublin). 1493 livers were offered to hepatoblastoma/prioritised paediatric/ACLF patients and 174 were accepted and transplanted. 573 livers were offered to the liver and intestinal list and 56 were accepted and transplanted. Please note that a liver accepted and used at any stage may have been provisionally offered on to elective patients or fast-tracked before being accepted and used. These have not been included in the number of livers offered in later stages along with livers that may have been accepted, split and transplanted into two patients.


3.4.8. 1099 livers were offered to liver and cardiothoracic patients and nine were accepted and transplanted combined liver and cardiothoracic patients. It should be noted that offers may be made when the cardiothoracic organs are unavailable.

3.4.9. **Figure 9b** shows the number of livers that were offered to elective patients and hadn't been accepted and used for super-urgent, hepatoblastoma, liver/intestinal and liver/cardiothoracic patients. Of the 5129 livers offered to elective patients, 5051 were adult donors and 78 were paediatric donors (aged less than 16 years or weighing 40 kg or less). 889 adult donors met the split criteria and 832 livers were offered to paediatric centres for paediatric/small adult patients. 268 of the 832 livers were accepted and transplanted. Fifty-six livers were only offered to paediatric patients and not offered to elective adult patient or fast-tracked.


3.4.10. 163 livers were offered to elective patients between 27 March and 9 July 2020.

3.4.11. Ninety percent of livers offered to elective patients were randomly allocated to the elective CLD/HCC pathway while ten percent were allocated to the variant syndrome pathway. 3999 were offered to named CLD/HCC patients and 2389 (60%) were accepted and transplanted. 418 were offered to the VS pathway and 209 (50%) were accepted and transplanted.

**Figure 9A Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 September 2025**



**Figure 9B Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 September 2025**




3.4.12. **Table 10** shows the number of liver offers made to each UK liver transplant centre in either the twelve months prior to the new scheme or during the first 90 of the new scheme. Livers offered to intestinal or liver/cardiothoracic patients have been excluded. The number of offers made to UK liver transplant centres has increased compared with the 12 months prior.


**Table 10 Number of DBD liver only offers (excludes intestinal and liver/cardiothoracic offers) per UK transplant centre, 20 March 2017 to 19 September 2025**

Period		Newcastle	Leeds	Cambridge	Royal Free	Kings College	Birmingham	Edinburgh	Total
2017/2018	No. offers (no. donors)	344 (323)	501 (435)	348 (323)	384 (352)	516 (455)	495 (417)	374 (351)	<b>2962 (944)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	<b>2 (1, 5)</b>
2018/2019	No. offers (no. donors)	431 (378)	645 (481)	480 (391)	566 (459)	1019 (638)	867 (582)	511 (426)	<b>4519 (982)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	<b>3 (2, 7)</b>
2019/2020	No. offers (no. donors)	432 (386)	733 (545)	455 (386)	489 (420)	902 (629)	829 (591)	470 (415)	<b>4310 (986)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	<b>3 (1, 7)</b>
2020/2021	No. offers (no. donors)	402 (343)	632 (443)	434 (352)	463 (368)	809 (531)	673 (468)	509 (395)	<b>3922 (777)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	<b>4 (1, 8)</b>
2021/2022	No. offers (no. donors)	315 (285)	611 (444)	400 (347)	479 (375)	919 (564)	730 (487)	406 (345)	<b>3860 (785)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	<b>4 (1, 8)</b>
20 Mar – 3 Oct 22	No. offers (no. donors)	162 (141)	303 (228)	212 (187)	195 (152)	417 (262)	382 (253)	203 (175)	<b>1874 (415)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	<b>3 (1, 7)</b>
4 Oct 22 – 3 Oct 23	No. offers (no. donors)	282 (258)	577 (423)	358 (299)	383 (325)	1240 (603)	744 (466)	374 (326)	<b>3958 (764)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	2 (1, 3)	1 (1, 2)	1 (1, 1)	<b>4 (2, 8)</b>
4 Oct 23 – 3 Oct 24	No. offers (no. donors)	290 (257)	574 (420)	405 (328)	394 (323)	774 (496)	691 (445)	398 (334)	<b>3526 (729)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	<b>4 (2, 8)</b>
4 Oct 24 – 19 Sep 25	No. offers (no. donors)	201 (187)	515 (358)	268 (233)	282 (242)	558 (400)	521 (344)	345 (289)	<b>2690 (625)</b>
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	<b>3 (2, 7)</b>

3.4.13. **Figure 10** shows, for livers that were ultimately transplanted, the outcome of liver offers made in either the last year prior to the new scheme or during the first 90 months of the new scheme. The last time periods have been split as the parameter estimates and baseline survivor functions were updated on 4 October 2022. Fast-track offers that were not accepted and transplanted (i.e. declined or accepted and not used fast-track offers) as well as livers offered from either DCD or positive virology donors were excluded. It should be noted that offers of left and right lobes are included. The proportion of offers accepted and not used has increased compared with the 12 months prior. **Figure 10A** shows the equivalent for each transplant centre.



**Figure 10A Offer outcome, by centre, for DBD livers that were offered and ultimately transplanted, 20 March 2017 to 19 September 2025**



3.4.14. 9915 (35%) of the 28659 offers made in the first 90 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 6788 of the named patient offers involved livers that were ultimately retrieved and transplanted.

3.4.15. The number of named patient offers per donor ranged between 1 and 18 with a median of two named patient offers per donor. The number of named offers per patient ranged between 1 and 34 with a median of two offers per patient.

3.4.16. Sixty nine patients at 7 centres were offered 11 or more livers in the 90 month time period (17 were offered 11 livers, 17 were offered 12 livers, 12 were offered 13 livers, 9 were offered 14 livers, 4 were offered 15 livers, 1 was offered 16, 1 were offered 17, 2 were offered 18 livers, 1 was offered 19 livers, 1 was offered 21, 2 were offered 27, 1 was offered 28 and 1 was offered 34 livers). Ten of the sixty-nine patients offered 11 or more livers in the 90 month time period were on the variant syndrome pathway, 4 were on the HCC pathway and 55 were on the CLD pathway.

3.4.17. **Table 11** shows the outcome of named patient liver offers made during the first 90 months of the new scheme by type of patient. It also shows the offer outcome after excluding named patients offers for livers that were ultimately not transplanted. Overall, forty-six percent of named patient offers were accepted and 26% were accepted and transplanted. The number of transplants will not agree with the flow chart in **Figure 9A** as **Table 11** includes all elective named patient offers and will include livers that were offered as a right lobe after being accepted for super-urgent and hepatoblastoma patients.

3.4.18. **Figures 11A, 11B and 11C** shows the outcome of named CLD patient liver offers made during the first 90 months of the new scheme for livers ultimately transplanted by aetiology, transplant centre and blood group respectively. There were statistically significant differences at a 5% significance level in the outcomes for patients with ALD ( $p=0.003$ ) and AID ( $p=0.018$ ). Although the number of offers has decreased for patients with other disease group, there was no evidence of a statistically significant difference in outcomes ( $p=0.74$ ).


3.4.19. **Figures 12A and 12B** for shows the outcome of named HCC patient liver offers made during the first 90 months of the new scheme for livers ultimately transplanted by transplant centre and blood group respectively. **Figures 13A and 13B** show equivalent information for variant syndrome patients.

**Table 11 Offer outcome for named elective patient offers made between 20 March 2018 and 19 September 2025 (excluding 27 March 2020 to 9 July 2020), by type of patient**


Type of patient	Disease group	Offer outcome for all named patient offers				Offer outcome for all named patient offers for livers that were ultimately transplanted			
		Declined	Accepted but not used	Transplanted	Total	Declined	Accepted but not used	Transplanted	Total
Chronic Liver Disease (CLD)	2018/2019	789 (55)	246 (17)	409 (28)	1444	491 (47)	142 (14)	409 (39)	1042
	2019/2020	613 (50)	250 (20)	361 (29)	1224	346 (42)	118 (14)	361 (44)	825
	2020/2021 <sup>1</sup>	544 (59)	162 (17)	223 (24)	929	315 (51)	78 (13)	223 (36)	616
	2021/2022	796 (58)	252 (18)	336 (24)	1384	493 (51)	131 (14)	336 (35)	960
	20 Mar – 3 Oct 22	290 (51)	110 (19)	169 (30)	569	202 (47)	57 (13)	169 (39)	428
	4 Oct 22 – 3 Oct 23	508 (51)	194 (20)	286 (29)	988	267 (42)	89 (14)	286 (45)	642
	4 Oct 23 – 3 Oct 24	497 (51)	220 (23)	250 (26)	967	288 (45)	99 (16)	250 (39)	637
	4 Oct 24 – 19 Sep 25	362 (45)	201 (25)	244 (30)	807	208 (38)	89 (16)	244 (45)	541
	<b>Total</b>	<b>4399 (53)</b>	<b>1635 (20)</b>	<b>2278 (27)</b>	<b>8312</b>	<b>2610 (46)</b>	<b>803 (14)</b>	<b>2278 (40)</b>	<b>5691</b>
HCC	2018/2019	31 (53)	12 (20)	16 (27)	59	24 (53)	5 (11)	16 (36)	45
	2019/2020	29 (44)	12 (18)	25 (38)	66	11 (24)	9 (20)	25 (56)	45
	2020/2021 <sup>1</sup>	31 (57)	13 (24)	10 (19)	54	25 (61)	6 (15)	10 (24)	41
	2021/2022	39 (58)	11 (16)	17 (25)	67	17 (44)	5 (13)	17 (44)	39
	20 Mar – 3 Oct 22	27 (60)	8 (18)	10 (22)	45	22 (61)	4 (11)	10 (28)	36
	4 Oct 22 – 3 Oct 23	59 (53)	26 (23)	26 (23)	111	24 (43)	6 (11)	26 (46)	56
	4 Oct 23 – 3 Oct 24	49 (46)	29 (27)	29 (27)	107	25 (40)	8 (13)	29 (47)	62
	4 Oct 24 – 19 Sep 25	23 (39)	17 (29)	19 (32)	59	10 (26)	9 (24)	19 (50)	38
	<b>Total</b>	<b>288 (51)</b>	<b>128 (23)</b>	<b>152 (27)</b>	<b>568</b>	<b>158 (44)</b>	<b>52 (14)</b>	<b>152 (42)</b>	<b>362</b>
Variant syndrome	2018/2019	80 (56)	27 (19)	35 (25)	142	55 (53)	14 (13)	35 (34)	104
	2019/2020	92 (58)	28 (18)	39 (25)	159	66 (55)	16 (13)	39 (32)	121
	2020/2021 <sup>1</sup>	58 (64)	19 (21)	13 (14)	90	22 (50)	9 (20)	13 (30)	44
	2021/2022	132 (68)	38 (19)	25 (13)	195	94 (65)	26 (18)	25 (17)	145
	20 Mar – 3 Oct 22	49 (65)	13 (17)	13 (17)	75	30 (60)	7 (14)	13 (26)	50
	4 Oct 22 – 3 Oct 23	68 (63)	16 (15)	24 (22)	108	43 (59)	6 (8)	24 (33)	73
	4 Oct 23 – 3 Oct 24	93 (60)	30 (19)	33 (21)	156	61 (53)	21 (18)	33 (29)	115
	4 Oct 24 – 19 Sep 25	66 (60)	17 (15)	27 (25)	110	43 (52)	13 (16)	27 (33)	83
	<b>Total</b>	<b>638 (62)</b>	<b>188 (18)</b>	<b>209 (20)</b>	<b>1035</b>	<b>414 (56)</b>	<b>112 (15)</b>	<b>209 (28)</b>	<b>735</b>
<b>Total named patient offers</b>		<b>5325 (54)</b>	<b>1951 (20)</b>	<b>2639 (26)</b>	<b>9915</b>	<b>3182 (47)</b>	<b>967 (14)</b>	<b>2639 (39)</b>	<b>6788</b>

<sup>1</sup> Offers between 27 March 2020 and 9 July excluded


**Figure 11A** Named CLD patient offer outcome, by year and disease group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding offers between 27 March and 9 July 2020)




**Figure 11B** Named CLD patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding offers between 27 March and 9 July 2020)




**Figure 11C** Named CLD patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding offers between 27 March and 9 July 2020)




**Figure 12A** Named HCC patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding offers between 27 March and 9 July 2020)




**Figure 12B** Named HCC patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding offers between 27 March and 9 July 2020)



**Figure 13A** Named VS patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding offers between 27 March and 9 July 2020)



**Figure 13B** Named VS patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding offers between 27 March and 9 July 2020)



3.4.20. **Table 12A, 12B, 12C** and **Figures 14A, 14B** and **14C** show the median Transplant Benefit Score (TBS) at time of offer for named elective patient offers for *livers ultimately transplanted* by, separately, aetiology, centre and blood group. Overall, the median TBS for CLD ranged between 1123 and 1227 days by year for the original NLOS.

3.4.21. **Table 13** shows the median Transplant Benefit Score (TBS) at time of offer for named elective HCC patient offers for *livers ultimately transplanted* by UKELD group.

**Table 12A Median (IQR) Transplant Benefit Score (TBS) for named elective patient offers for livers ultimately transplanted, by disease group, 20 March 2018 to 19 September 2025 (excluding 27 March 2020 to 9 July 2020)**

		2018/19	2019/20	2020/21	2021/22	20 March – 3 October 2022	4 October 22 – 3 October 23	4 October 23 – 3 October 24	4 October 24 – 19 September 25
<b>Disease group</b>									
HCC	N	45	45	41	39	36	56	62	38
	Median (IQR)	1106 (676 - 1315)	980 (775 - 1089)	463 (192 - 973)	938 (543 - 1152)	1276 (1137 - 1417)	1079 (894 - 1195)	1022 (870 - 1167)	1178 (1013 - 1231)
Hepatitis C	N	33	19	17	24	13	9	13	5
	Median (IQR)	1057 (920 - 1251)	1170 (926 - 1392)	1107 (994 - 1304)	1239 (1056 - 1376)	1185 (1097 - 1288)	1177 (1097 - 1199)	1122 (963 - 1265)	990 (940 - 1174)
ALD	N	280	264	192	315	110	245	216	183
	Median (IQR)	1246 (1032 - 1351)	1230 (1080 - 1353)	1185 (976 - 1307)	1212 (1026 - 1348)	1236 (1103 - 1367)	1226 (1087 - 1382)	1208 (1028 - 1400)	1246 (1085 - 1426)
Hepatitis B	N	18	6	7	14	2	15	0	14
	Median (IQR)	1062 (971 - 1380)	1182 (998 - 1406)	1370 (1261 - 1555)	971 (833 - 1221)	1216 (1165 - 1267)	1132 (988 - 1238)	-	1113 (1001 - 1247)
PSC	N	105	98	83	126	56	95	98	71
	Median (IQR)	1199 (1017 - 1316)	1179 (1092 - 1281)	1084 (838 - 1221)	1167 (968 - 1258)	1187 (989 - 1303)	1078 (909 - 1239)	1123 (1005 - 1295)	1140 (1029 - 1232)
PBC	N	86	56	74	75	48	45	51	42
	Median (IQR)	1081 (1007 - 1223)	1089 (1015 - 1212)	1091 (949 - 1256)	1037 (870 - 1227)	1237 (1081 - 1262)	1108 (998 - 1209)	971 (876 - 1185)	1073 (979 - 1218)
AID	N	130	69	42	80	30	39	20	25
	Median (IQR)	1263 (1109 - 1379)	1202 (1005 - 1332)	1284 (1202 - 1354)	1215 (994 - 1432)	1290 (1234 - 1442)	1314 (1158 - 1450)	1137 (951 - 1362)	1376 (1264 - 1519)
Metabolic	N	200	176	104	190	100	104	103	75
	Median (IQR)	1215 (1050 - 1326)	1169 (1041 - 1310)	1157 (1032 - 1265)	1243 (1082 - 1350)	1258 (1168 - 1338)	1083 (955 - 1192)	1106 (1013 - 1210)	1117 (1006 - 1240)
Other	N	28	26	28	36	21	7	15	11
	Median (IQR)	992 (797 - 1080)	996 (939 - 1163)	1042 (678 - 1168)	1062 (885 - 1246)	1176 (1149 - 1203)	1045 (223 - 1094)	1179 (626 - 1236)	1163 (1111 - 1196)
Retransplant	N	162	111	69	100	48	83	121	115
	Median (IQR)	1117 (1011 - 1236)	1074 (984 - 1199)	1011 (878 - 1122)	1103 (921 - 1238)	1154 (1087 - 1205)	1098 (1004 - 1210)	1060 (951 - 1164)	1120 (1030 - 1261)
Overall CLD	N	1042	825	616	960	428	642	637	541
	Median (IQR)	1178 (1017 - 1314)	1169 (1031 - 1303)	1124 (965 - 1274)	1179 (988 - 1304)	1227 (1121 - 1319)	1146 (1018 - 1303)	1123 (985 - 1278)	1160 (1038 - 1310)

**Table 12B Median (IQR) Transplant Benefit Score (TBS) for named elective patient offers for livers ultimately transplanted, by type of patient and centre, 20 March 2018 to 19 September 2025 (excluding 27 March 2020 to 9 July 2020)**

		2018/19	2019/20	2020/21	2021/22	20 March – 3 October 2022	4 October 22 – 3 October 23	4 October 23 – 3 October 24	4 October 24 – 19 September 25
<b>HCC</b>									
Newcastle	N	0	2	5	4	0	1	1	0
	Median (IQR)	-	1161 (1034 - 1289)	-14 (-55 - 570)	564 (254 - 697)	-	1314 (1314 - 1314)	1244 (1244 - 1244)	-
Leeds	N	1	16	10	6	20	17	15	11
	Median (IQR)	668 (668 - 668)	971 (901 - 1090)	484 (-6 - 854)	993 (968 - 1036)	1179 (1129 - 1410)	1126 (1025 - 1249)	956 (857 - 1149)	1091 (938 - 1179)
Cambridge	N	10	2	6	4	3	9	11	2
	Median (IQR)	1322 (1265 - 1458)	867 (297 - 1437)	292 (65 - 705)	1196 (553 - 1254)	1518 (1212 - 1530)	884 (858 - 899)	915 (881 - 1049)	918 (751 - 1086)
Royal Free	N	9	7	0	3	0	1	2	1
	Median (IQR)	1313 (676 - 1409)	507 (242 - 943)	-	1116 (643 - 1152)	-	1405 (1405 - 1405)	1249 (1221 - 1278)	1180 (1180 - 1180)
Kings College	N	7	8	7	13	3	11	16	11
	Median (IQR)	598 (515 - 1104)	1060 (1051 - 1105)	463 (415 - 1318)	1075 (910 - 1371)	1190 (1000 - 1339)	1194 (1121 - 1262)	1081 (937 - 1194)	1190 (980 - 1265)
Birmingham	N	9	6	5	5	3	11	6	3
	Median (IQR)	1026 (642 - 1179)	923 (549 - 1062)	1090 (1051 - 1103)	448 (-103 - 582)	1203 (766 - 1365)	1012 (925 - 1080)	768 (507 - 1113)	1178 (1076 - 1437)
Edinburgh	N	9	4	8	4	7	6	11	10
	Median (IQR)	1081 (1052 - 1120)	784 (470 - 1020)	339 (236 - 831)	651 (331 - 1063)	1405 (1359 - 1424)	716 (670 - 948)	1026 (982 - 1147)	1197 (1178 - 1270)
<b>CLD</b>									
Newcastle	N	82	65	51	65	21	17	31	22
	Median (IQR)	1255 (1085 - 1340)	1128 (1064 - 1280)	1068 (952 - 1264)	1259 (1184 - 1352)	1169 (983 - 1257)	1236 (1055 - 1346)	1105 (957 - 1224)	1120 (967 - 1201)
Leeds	N	103	99	94	129	65	115	120	106
	Median (IQR)	1097 (923 - 1289)	1183 (1031 - 1309)	1094 (932 - 1235)	1186 (1064 - 1288)	1250 (1158 - 1353)	1164 (1072 - 1255)	1174 (1049 - 1255)	1161 (1077 - 1364)
Cambridge	N	106	112	77	122	60	91	73	58
	Median (IQR)	1205 (997 - 1306)	1223 (1084 - 1310)	1122 (994 - 1224)	1158 (978 - 1313)	1260 (1177 - 1332)	1121 (1041 - 1303)	1120 (1004 - 1301)	1219 (1047 - 1337)
Royal Free	N	166	109	92	121	50	70	72	55
	Median (IQR)	1190 (996 - 1342)	1154 (1037 - 1255)	1102 (930 - 1276)	1176 (1027 - 1308)	1183 (1153 - 1319)	1154 (954 - 1316)	1204 (1005 - 1375)	1213 (1105 - 1296)
Kings College	N	241	192	116	208	76	129	116	107
	Median (IQR)	1169 (1025 - 1310)	1147 (1006 - 1336)	1165 (1011 - 1254)	1153 (965 - 1266)	1206 (1089 - 1272)	1165 (1029 - 1305)	1108 (968 - 1244)	1120 (979 - 1290)
Birmingham	N	224	172	85	202	86	129	127	99
	Median (IQR)	1198 (1057 - 1318)	1153 (1016 - 1297)	1162 (917 - 1350)	1127 (958 - 1300)	1172 (1054 - 1303)	1132 (992 - 1284)	1048 (948 - 1248)	1147 (1035 - 1278)
Edinburgh	N	120	76	101	113	70	91	98	94
	Median (IQR)	1132 (1008 - 1283)	1175 (1041 - 1315)	1147 (1032 - 1270)	1258 (1120 - 1345)	1253 (1175 - 1328)	1124 (998 - 1323)	1103 (975 - 1358)	1196 (1056 - 1329)

**Table 12C Median (IQR) Transplant Benefit Score (TBS) for named elective patient offers for livers ultimately transplanted, by type of patient and blood group, 20 March 2018 to 19 September 2025 (excluding 27 March 2020 to 9 July 2020)**

	2018/19	2019/20	2020/21	2021/22	20 March – 3 October 2022	4 October 22 – 3 October 23	4 October 23 – 3 October 24	4 October 24 – 19 Sept 25
<b>HCC</b>								
O	N 19 Median (IQR) 1285 (1105 - 1381)	N 13 Median (IQR) 1062 (474 - 1164)	N 8 Median (IQR) 914 (704 - 1305)	N 6 Median (IQR) 1134 (904 - 1187)	N 17 Median (IQR) 1385 (1339 - 1425)	N 12 Median (IQR) 1122 (1021 - 1178)	N 27 Median (IQR) 1120 (1026 - 1181)	N 14 Median (IQR) 1081 (1013 - 1180)
A	N 17 Median (IQR) 1256 (855 - 1329)	N 21 Median (IQR) 1034 (920 - 1164)	N 23 Median (IQR) 402 (65 - 915)	N 28 Median (IQR) 953 (646 - 1196)	N 14 Median (IQR) 1144 (1025 - 1186)	N 33 Median (IQR) 1076 (890 - 1249)	N 27 Median (IQR) 959 (851 - 1042)	N 15 Median (IQR) 1203 (1179 - 1268)
B	N 4 Median (IQR) 672 (629 - 698)	N 4 Median (IQR) 958 (851 - 990)	N 5 Median (IQR) 355 (192 - 1028)	N 1 Median (IQR) 943 (943 - 943)	N 4 Median (IQR) 1485 (1415 - 1524)	N 11 Median (IQR) 1068 (858 - 1195)	N 5 Median (IQR) 953 (914 - 1235)	N 5 Median (IQR) 980 (695 - 1130)
AB	N 5 Median (IQR) 545 (515 - 598)	N 7 Median (IQR) 549 (348 - 899)	N 5 Median (IQR) 276 (-55 - 415)	N 4 Median (IQR) 373 (144 - 515)	N 1 Median (IQR) 232 (232 - 232)	N 0 Median (IQR) -	N 3 Median (IQR) 738 (406 - 834)	N 4 Median (IQR) 678 (542 - 1008)
<b>CLD</b>								
O	N 460 Median (IQR) 1189 (1057 - 1331)	N 360 Median (IQR) 1234 (1113 - 1346)	N 246 Median (IQR) 1210 (1071 - 1306)	N 379 Median (IQR) 1253 (1152 - 1346)	N 176 Median (IQR) 1268 (1217 - 1349)	N 289 Median (IQR) 1188 (1094 - 1345)	N 288 Median (IQR) 1198 (1053 - 1336)	N 209 Median (IQR) 1238 (1140 - 1364)
A	N 429 Median (IQR) 1190 (997 - 1313)	N 343 Median (IQR) 1082 (976 - 1233)	N 269 Median (IQR) 1068 (905 - 1211)	N 438 Median (IQR) 1081 (919 - 1259)	N 188 Median (IQR) 1164 (1051 - 1256)	N 240 Median (IQR) 1102 (976 - 1277)	N 283 Median (IQR) 1059 (938 - 1185)	N 231 Median (IQR) 1117 (1014 - 1258)
B	N 88 Median (IQR) 1140 (963 - 1291)	N 71 Median (IQR) 1193 (1061 - 1285)	N 74 Median (IQR) 1107 (972 - 1344)	N 106 Median (IQR) 1190 (971 - 1293)	N 46 Median (IQR) 1182 (1057 - 1299)	N 75 Median (IQR) 1066 (947 - 1239)	N 45 Median (IQR) 1210 (1044 - 1308)	N 60 Median (IQR) 1100 (885 - 1329)
AB	N 65 Median (IQR) 978 (640 - 1269)	N 51 Median (IQR) 1046 (876 - 1363)	N 27 Median (IQR) 1045 (765 - 1126)	N 37 Median (IQR) 813 (460 - 1137)	N 18 Median (IQR) 1188 (906 - 1284)	N 38 Median (IQR) 1074 (853 - 1148)	N 21 Median (IQR) 890 (709 - 990)	N 38 Median (IQR) 945 (778 - 1193)

**Table 13 Median (IQR) Transplant Benefit Score (TBS) for named elective HCC patient offers for livers ultimately transplanted, by UKELD score group, 20 March 2018 to 19 September 2025 (excluding 27 March 2020 to 9 July 2020)**

	2018/19	2019/20	2020/21	2021/22	20 March – 3 October 2022	4 October 22 – 3 October 23	4 October 23 – 3 October 24	4 October 24 – 19 Sept 25
<b>&lt;49</b>								
	N 1 Median (IQR) 591 (591 - 591)	N 9 Median (IQR) 297 (182 - 507)	N 15 Median (IQR) 70 (-6 - 415)	N 4 Median (IQR) 9 (-57 - 163)	N 1 Median (IQR) 232 (232 - 232)	N 7 Median (IQR) 758 (670 - 884)	N 11 Median (IQR) 858 (584 - 915)	N 2 Median (IQR) 808 (636 - 980)
49-53	N 8 Median (IQR) 607 (497 - 695)	N 9 Median (IQR) 916 (810 - 980)	N 12 Median (IQR) 730 (232 - 1070)	N 13 Median (IQR) 643 (448 - 1036)	N 1 Median (IQR) 766 (766 - 766)	N 27 Median (IQR) 1068 (939 - 1139)	N 25 Median (IQR) 956 (859 - 1167)	N 12 Median (IQR) 1049 (723 - 1147)
≥ 54	N 36 Median (IQR) 1261 (1059 - 1358)	N 27 Median (IQR) 1054 (943 - 1227)	N 14 Median (IQR) 914 (767 - 1289)	N 22 Median (IQR) 1029 (910 - 1254)	N 34 Median (IQR) 1343 (1159 - 1424)	N 22 Median (IQR) 1145 (1079 - 1305)	N 26 Median (IQR) 1108 (1042 - 1192)	N 24 Median (IQR) 1191 (1127 - 1265)

Figure 14A Median Transplant Benefit Score (TBS) for named elective chronic liver disease patient offers for livers ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding 27 March 2020 to 9 July 2020), by aetiology




Figure 14B Median Transplant Benefit Score (TBS) for named elective chronic liver disease patient offers for livers ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding 27 March 2020 to 9 July 2020), by transplant centre





Figure 14C Median Transplant Benefit Score (TBS) for named elective chronic liver disease patient offers for livers ultimately transplanted, 20 March 2018 to 19 September 2025 (excluding 27 March 2020 to 9 July 2020), by blood group



### 3.5. TRANSPLANT ACTIVITY

3.5.1. **Table 14** shows the urgency status and age group of DBD and DCD liver transplants performed in the UK between 20 March 2017 and 19 September 2025. The proportion of super-urgent transplants performed has increased from prior to NLOS implementation to 2022/23 (11% vs 14% respectively). In years since 2022/23, the proportion of super-urgent transplants performed has been similar to the year prior to NLOS (11% in 2017/18) and, more recently, between 20 March 2025 and 19 September 2025, 7% of transplants were super-urgent. There was no evidence of a statistically significant difference in proportion of super-urgent transplants between years for adult DBD liver and adult liver/kidney transplants (overall Chi-squared p-value=0.10) or for paediatric transplants (overall Chi-squared p-value=0.10). Highlighted in red are the transplants that will be analysed further in the rest of the section.


**Table 14 Urgency status and age group for deceased donor liver transplants performed in the UK, 20 March 2017 to 19 September 2025, as at 10 October 2025**

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)	2023/24 N (%)	2024/25 N (%)	2025/26* N (%)
<b>DBD liver</b>									
Adult elective liver and liver/kidney	640 (78.1)	623 (77.6)	608 (77.8)	477 (76.8)	481 (74.6)	449 (70.7)	452 (75.3)	415 (73.6)	211 (76.7)
Adult elective liver/cardiothoracic	2 (0.2)	0 (0)	2 (0.3)	3 (0.5)	3 (0.5)	1 (0.2)	0 (0)	0 (0)	0 (0)
Adult elective multivisceral	6 (0.7)	5 (0.6)	6 (0.8)	1 (0.2)	9 (1.4)	8 (1.3)	4 (0.7)	5 (0.9)	0 (0)
Adult super-urgent liver and liver/kidney	94 (11.5)	100 (12.5)	83 (10.6)	61 (9.8)	75 (11.6)	96 (15.1)	77 (12.8)	75 (13.3)	31 (11.3)
Adult super-urgent multivisceral	1 (0.1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	0 (0)
Paediatric elective liver and liver/kidney	57 (7.0)	55 (6.8)	64 (8.2)	63 (10.1)	53 (8.2)	53 (8.3)	48 (8.0)	51 (9.0)	30 (10.9)
Paediatric elective multivisceral	6 (0.7)	3 (0.4)	2 (0.3)	4 (0.6)	2 (0.3)	3 (0.5)	3 (0.5)	3 (0.5)	1 (0.4)
Paediatric super-urgent liver and liver/kidney	13 (1.6)	17 (2.1)	16 (2)	12 (1.9)	22 (3.4)	24 (3.8)	16 (2.7)	15 (2.7)	2 (0.7)
<b>Total UK DBD transplants</b>	<b>819 (100)</b>	<b>803 (100)</b>	<b>781 (100)</b>	<b>621 (100)</b>	<b>645 (100)</b>	<b>635 (100)</b>	<b>600 (100)</b>	<b>564 (100)</b>	<b>275 (100)</b>
<b>DCD liver</b>									
Adult elective liver and liver/kidney	190 (96.0)	185 (96.9)	173 (97.7)	110 (95.7)	189 (97.9)	243 (97.6)	257 (97.3)	310 (98.4)	194 (99.5)
Adult elective liver/cardiothoracic	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)
Adult super-urgent liver and liver/kidney	1 (0.5)	1 (0.5)	3 (1.7)	2 (1.7)	2 (1.0)	1 (0.4)	2 (0.8)	1 (0.3)	1 (0.5)
Paediatric elective liver and liver/kidney	7 (3.5)	4 (2.1)	1 (0.6)	2 (1.7)	2 (1.0)	5 (2.0)	4 (1.5)	3 (1.0)	0 (0)
Paediatric super-urgent liver and liver/kidney	0 (0)	1 (0.5)	0 (0)	1 (0.9)	0 (0)	0 (0)	0 (0)	1 (0.3)	0 (0)
<b>Total UK DCD transplants</b>	<b>198 (100)</b>	<b>191 (100)</b>	<b>177 (100)</b>	<b>115 (100)</b>	<b>193 (100)</b>	<b>249 (100)</b>	<b>264 (100)</b>	<b>315 (100)</b>	<b>195 (100)</b>
<b>Total UK transplants</b>	<b>1017 (100)</b>	<b>994 (100)</b>	<b>958 (100)</b>	<b>736 (100)</b>	<b>838 (100)</b>	<b>884 (100)</b>	<b>864 (100)</b>	<b>879 (100)</b>	<b>470 (100)</b>

\*Six months included, up to 19 September 2025

3.5.2. **Figure 15** shows the number of transplants over the time periods of interest, by transplant centre and donor type.

**Figure 15** Number of deceased donor liver transplants performed in the UK by transplant centre and donor type, 20 March 2017 - 19 September 2025



\*Six months included, up to 19 September 2025

3.5.3. One hundred and forty of the adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are **included** in the rest of the section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients. Sixteen NHS group 2 transplants (1 performed at London Bridge and 15 performed at King's College) and three intestinal liver only transplants performed at Cambridge between August 2017 and September 2018 have been excluded from the rest of this section.

3.5.4. **Table 15** and **Table 16** show the demographics of adult elective liver and liver/kidney DBD and DCD transplants performed in the UK during the time periods of interest.

**Table 15 Adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 September 2025, as at 10 October 2025**

	2017/18 N (%) 635	2018/19 N (%) 621	2019/20 N (%) 607	2020/21 N (%) 476	2021/22 N (%) 481	2022/23 N (%) 449	2023/24 N (%) 452	2024/25 N (%) 415	2025/26* N (%) 211
<b>Total</b>									
<b>Offer type</b>									
Named patient	491 (79.1)	441 (72.7)	344 (72.3)	395 (82.1)	378 (84.2)	362 (80.1)	315 (75.9)	170 (80.6)	
Fast-track	130 (20.9)	166 (27.3)	132 (27.7)	86 (17.9)	71 (15.8)	90 (19.9)	100 (24.1)	41 (19.4)	
<b>Rank on matching run</b>									
Median (IQR)	2 (1 - 4)	2 (1 - 4)	2 (1 - 5)	2 (1 - 4)	2 (1 - 3)	2 (1 - 4)	2 (1 - 4)	2 (1 - 3)	
(Range)	(1 - 187)	(1 - 191)	(1 - 204)	(1 - 363)	(1 - 415)	(1 - 317)	(1 - 280)	(1 - 178)	
<b>Transplant Benefit Score</b>									
Median (IQR)	1131.98 (881 – 1301)	1096.12 (885 – 1289)	1090.12 (838 – 1281)	1155.1 (923 – 1314)	1170.78 (1014 – 1317)	1136.7 (953 – 1314)	1105.8 (897 – 1241)	1152.9 (1000 – 1306)	
(Range)	(-493 – 1617)	(-549 – 1616)	(-1535 – 1563)	(-289 – 1600)	(-215 – 1635)	(-52 – 1601)	(-164 – 1649)	(73 – 1593)	
<b>Transplant Type</b>									
Liver only	615 (96.9)	608 (97.9)	593 (97.7)	469 (98.5)	475 (98.8)	443 (98.7)	445 (98.5)	411 (99.0)	210 (99.5)
Liver & kidney	20 (3.1)	13 (2.1)	14 (2.3)	7 (1.5)	6 (1.2)	6 (1.3)	7 (1.5)	4 (1.0)	1 (0.5)
<b>Type of Liver Transplanted</b>									
Whole liver	596 (93.9)	581 (93.6)	569 (93.7)	443 (93.1)	447 (92.9)	419 (93.3)	422 (93.4)	384 (92.5)	194 (91.9)
Split liver	39 (6.1)	40 (6.4)	37 (6.1)	33 (6.9)	34 (7.1)	28 (6.2)	29 (6.4)	30 (7.2)	17 (8.1)
Reduced liver	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	2 (0.4)	1 (0.2)	1 (0.2)	0 (0)
<b>Recipient Age Group</b>									
17-25 years	27 (4.3)	37 (6.0)	35 (5.8)	34 (7.1)	25 (5.2)	22 (4.9)	21 (4.6)	21 (5.1)	8 (3.8)
26-39 years	95 (15.0)	68 (11.0)	64 (10.5)	41 (8.6)	49 (10.2)	47 (10.5)	58 (12.8)	51 (12.3)	20 (9.5)
40-49 years	98 (15.4)	75 (12.1)	68 (11.2)	78 (16.4)	85 (17.7)	53 (11.8)	55 (12.2)	51 (12.3)	30 (14.2)
50-59 years	208 (32.8)	201 (32.4)	213 (35.1)	170 (35.7)	133 (27.7)	131 (29.2)	126 (27.9)	121 (29.2)	60 (28.4)
60-69 years	193 (30.4)	232 (37.4)	212 (34.9)	144 (30.3)	174 (36.2)	187 (41.6)	182 (40.3)	161 (38.8)	84 (39.8)
70+ years	14 (2.2)	8 (1.3)	15 (2.5)	9 (1.9)	15 (3.1)	9 (2.0)	10 (2.2)	10 (2.4)	9 (4.3)
<b>Recipient Sex</b>									
Male	395 (62.2)	395 (63.6)	369 (60.8)	297 (62.4)	318 (66.1)	275 (61.2)	287 (63.5)	258 (62.2)	130 (61.6)
Female	240 (37.8)	226 (36.4)	238 (39.2)	179 (37.6)	163 (33.9)	174 (38.8)	165 (36.5)	157 (37.8)	81 (38.4)

Demographic and Clinical Characteristics of Patients									
Demographic		Clinical		Treatment		Outcome		Other	
Type of Patient	Count (%)								
CLD	477 (75.1)	485 (78.1)	471 (77.6)	398 (83.6)	401 (83.4)	362 (80.6)	338 (74.8)	313 (75.4)	161 (76.3)
HCC	104 (16.4)	72 (11.6)	80 (13.2)	54 (11.3)	39 (8.1)	45 (10.0)	57 (12.6)	44 (10.6)	20 (9.5)
VS	49 (7.7)	59 (9.5)	51 (8.4)	21 (4.4)	28 (5.8)	29 (6.5)	35 (7.7)	36 (8.7)	18 (8.5)
ACLF	0 (0)	0 (0)	0 (0)	0 (0)	10 (2.1)	13 (2.9)	21 (4.6)	22 (5.3)	11 (5.2)
HCC downstaging	5 (0.8)	5 (0.8)	5 (0.8)	3 (0.6)	3 (0.6)	0 (0)	1 (0.2)	0 (0)	1 (0.5)
<b>Robert's Disease Group</b>									
HCC	109 (17.2)	78 (12.6)	85 (14.0)	57 (12.0)	45 (9.4)	49 (10.9)	58 (12.8)	49 (11.8)	22 (10.4)
HCV	23 (3.6)	12 (1.9)	16 (2.6)	9 (1.9)	6 (1.2)	4 (0.9)	7 (1.5)	8 (1.9)	0 (0)
ALD	139 (21.9)	169 (27.2)	153 (25.2)	127 (26.7)	149 (31.0)	136 (30.3)	128 (28.3)	114 (27.5)	67 (31.8)
HBV	8 (1.3)	13 (2.1)	5 (0.8)	2 (0.4)	11 (2.3)	7 (1.6)	6 (1.3)	5 (1.2)	5 (2.4)
PSC	86 (13.5)	72 (11.6)	63 (10.4)	47 (9.9)	56 (11.6)	57 (12.7)	71 (15.7)	54 (13.0)	29 (13.7)
PBC	37 (5.8)	49 (7.9)	47 (7.7)	43 (9.0)	37 (7.7)	33 (7.3)	29 (6.4)	29 (7.0)	13 (6.2)
AID	44 (6.9)	51 (8.2)	48 (7.9)	38 (8.0)	38 (7.9)	27 (6.0)	33 (7.3)	24 (5.8)	12 (5.7)
NAFLD	67 (10.6)	71 (11.4)	71 (11.7)	54 (11.3)	68 (14.1)	69 (15.4)	56 (12.4)	54 (13.0)	20 (9.5)
Metabolic (excl. NAFLD)	8 (1.3)	13 (2.1)	23 (3.8)	7 (1.5)	9 (1.9)	9 (2.0)	8 (1.8)	9 (2.2)	2 (0.9)
Other	58 (9.1)	40 (6.4)	44 (7.2)	38 (8.0)	35 (7.3)	27 (6.0)	30 (6.6)	33 (8.0)	19 (9)
Retransplant	56 (8.8)	53 (8.5)	52 (8.6)	54 (11.3)	27 (5.6)	31 (6.9)	26 (5.8)	36 (8.7)	22 (10.4)
<b>Liver Transplant Number</b>									
First liver transplant	579 (91.2)	567 (91.3)	555 (91.4)	421 (88.4)	454 (94.4)	418 (93.1)	426 (94.2)	379 (91.3)	189 (89.6)
Second	46 (7.2)	51 (8.2)	41 (6.8)	45 (9.5)	18 (3.7)	26 (5.8)	24 (5.3)	34 (8.2)	16 (7.6)
Third	7 (1.1)	3 (0.5)	8 (1.3)	9 (1.9)	8 (1.7)	4 (0.9)	2 (0.4)	2 (0.5)	6 (2.8)
Fourth	2 (0.3)	0 (0)	3 (0.5)	1 (0.2)	1 (0.2)	1 (0.2)	0 (0)	0 (0)	0 (0)
Sixth	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Blood Group Compatibility*</b>									
Identical	628 (98.9)	607 (97.7)	574 (94.6)	451 (94.7)	460 (95.8)	426 (94.9)	436 (96.7)	395 (95.2)	205 (97.2)
Compatible	6 (0.9)	14 (2.3)	33 (5.4)	25 (5.3)	20 (4.2)	23 (5.1)	15 (3.3)	20 (4.8)	6 (2.8)
Incompatible	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Zonal Transplants</b>									
Non zonal	167 (26.3)	487 (78.4)	486 (80.1)	398 (83.6)	389 (80.9)	360 (80.2)	365 (80.8)	342 (82.4)	180 (85.3)
Zonal	468 (73.7)	134 (21.6)	121 (19.9)	78 (16.4)	92 (19.1)	89 (19.8)	87 (19.2)	73 (17.6)	31 (14.7)

Blood group matching* (D=donor, R=recipient)									
DO, RO	297 (46.8)	294 (47.3)	262 (43.2)	182 (38.2)	171 (35.6)	156 (34.7)	212 (47.0)	168 (40.5)	89 (42.2)
DO, RA	1 (0.2)	0 (0)	3 (0.5)	5 (1.1)	8 (1.7)	7 (1.6)	7 (1.6)	6 (1.4)	2 (0.9)
DO, RB	1 (0.2)	1 (0.2)	5 (0.8)	5 (1.1)	5 (1)	6 (1.3)	3 (0.7)	5 (1.2)	1 (0.5)
DO, RAB	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.2)	0 (0)
DA, RO	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
DA, RA	245 (38.6)	235 (37.8)	235 (38.7)	203 (42.6)	213 (44.4)	217 (48.3)	156 (34.6)	167 (40.2)	88 (41.7)
DA, RAB	4 (0.6)	11 (1.8)	20 (3.3)	10 (2.1)	6 (1.3)	9 (2.0)	5 (1.1)	8 (1.9)	3 (1.4)
DB, RB	70 (11.0)	55 (8.9)	59 (9.7)	55 (11.6)	52 (10.8)	43 (9.6)	50 (11.1)	47 (11.3)	19 (9)
DB, RAB	0 (0)	2 (0.3)	5 (0.8)	5 (1.1)	1 (0.2)	1 (0.2)	0 (0)	0 (0)	0 (0)
DAB, RAB	16 (2.5)	23 (3.7)	18 (3)	11 (2.3)	24 (5.0)	10 (2.2)	18 (4.0)	13 (3.1)	9 (4.3)

\*2 transplants performed with unknown donor blood group, one in 2021/22 and one in 2023/24

**Table 16 Adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 September 2025, as at 10 October 2025**

	2017/18 N (%) 186	2018/19 N (%) 182	2019/20 N (%) 170	2020/21 N (%) 110	2021/22 N (%) 189	2022/23 N (%) 243	2023/24 N (%) 257	2024/25 N (%) 310	2025/26* N (%) 195
<b>Total</b>									
<b>Transplant Type</b>									
Liver only	186 (100)	182 (100)	169 (99.4)	110 (100)	189 (100)	241 (99.2)	254 (98.8)	307 (99.0)	194 (99.5)
Liver & kidney	0 (0)	0 (0)	1 (0.6)	0 (0)	0 (0)	2 (0.8)	3 (1.2)	3 (1.0)	1 (0.5)
<b>Recipient Age Group</b>									
17-25 years	4 (2.2)	5 (2.7)	5 (2.9)	1 (0.9)	1 (0.5)	5 (2.1)	1 (0.4)	4 (1.3)	3 (1.5)
26-39 years	10 (5.4)	17 (9.3)	16 (9.4)	14 (12.7)	19 (10.1)	30 (12.3)	31 (12.1)	30 (9.7)	34 (17.4)
40-49 years	24 (12.9)	23 (12.6)	25 (14.7)	17 (15.5)	35 (18.5)	39 (16.0)	36 (14.0)	63 (20.3)	33 (16.9)
50-59 years	76 (40.9)	73 (40.1)	55 (32.4)	36 (32.7)	83 (43.9)	82 (33.7)	83 (32.3)	109 (35.2)	60 (30.8)
60-69 years	66 (35.5)	58 (31.9)	68 (40.0)	39 (35.5)	48 (25.4)	82 (33.7)	101 (39.3)	99 (31.9)	58 (29.7)
70+ years	6 (3.2)	6 (3.3)	1 (0.6)	3 (2.7)	3 (1.6)	5 (2.1)	5 (1.9)	5 (1.6)	7 (3.6)
<b>Recipient Sex</b>									
Male	119 (64.0)	130 (71.4)	106 (62.4)	76 (69.1)	132 (69.8)	180 (74.1)	186 (72.4)	223 (71.9)	129 (66.2)
Female	67 (36.0)	52 (28.6)	64 (37.6)	34 (30.9)	57 (30.2)	63 (25.9)	71 (27.6)	87 (28.1)	66 (33.8)
<b>Type of Patient</b>									
CLD	123 (66.1)	87 (47.8)	107 (62.9)	72 (65.5)	104 (55.0)	145 (59.7)	164 (63.8)	205 (66.1)	132 (67.7)
HCC	52 (28.0)	83 (45.6)	58 (34.1)	33 (30.0)	73 (38.6)	84 (34.6)	75 (29.2)	81 (26.1)	47 (24.1)
VS	9 (4.8)	5 (2.7)	1 (0.6)	2 (1.8)	8 (4.2)	12 (4.9)	13 (5.1)	17 (5.5)	13 (6.7)
HCC downstaging	2 (1.1)	7 (3.8)	4 (2.4)	3 (2.7)	3 (1.6)	2 (0.8)	4 (1.6)	6 (1.9)	3 (1.5)
ACLF	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.5)	0 (0)	1 (0.4)	1 (0.3)	0 (0)
<b>Liver Transplant Number</b>									
First liver transplant	183 (98.4)	177 (97.3)	167 (98.2)	103 (93.6)	183 (96.8)	239 (98.4)	249 (96.9)	300 (96.8)	185 (94.9)
Second	3 (1.6)	5 (2.7)	3 (1.8)	7 (6.4)	4 (2.1)	3 (1.2)	7 (2.7)	10 (3.2)	8 (4.1)
Third	0 (0)	0 (0)	0 (0)	0 (0)	2 (1.1)	1 (0.4)	1 (0.4)	0 (0)	2 (1)
<b>Blood Group Compatibility</b>									
Identical	185 (99.5)	175 (96.2)	161 (94.7)	109 (99.1)	182 (96.3)	234 (96.3)	251 (97.7)	302 (97.4)	192 (99)
Compatible	1 (0.5)	7 (3.8)	9 (5.3)	1 (0.9)	7 (3.7)	9 (3.7)	6 (2.3)	8 (2.6)	2 (1)

Robert's Disease Group									
HCC	55 (29.6)	91 (50.0)	62 (36.5)	36 (32.7)	76 (40.2)	88 (36.2)	80 (31.1)	87 (28.1)	50 (25.6)
HCV	4 (2.2)	3 (1.6)	3 (1.8)	2 (1.8)	6 (3.2)	3 (1.2)	5 (1.9)	1 (0.3)	4 (2.1)
ALD	43 (23.1)	35 (19.2)	43 (25.3)	20 (18.2)	41 (21.7)	57 (23.5)	47 (18.3)	73 (23.5)	39 (20)
HBV	3 (1.6)	1 (0.5)	2 (1.2)	1 (0.9)	3 (1.6)	6 (2.5)	5 (1.9)	5 (1.6)	1 (0.5)
PSC	19 (10.2)	12 (6.6)	17 (10.0)	16 (14.5)	15 (7.9)	29 (11.9)	29 (11.3)	37 (11.9)	29 (14.9)
PBC	24 (12.9)	7 (3.8)	18 (10.6)	9 (8.2)	10 (5.3)	14 (5.8)	16 (6.2)	25 (8.1)	11 (5.6)
AID	10 (5.4)	7 (3.8)	5 (2.9)	4 (3.6)	10 (5.3)	14 (5.8)	20 (7.8)	23 (7.4)	15 (7.7)
NAFLD	21 (11.3)	13 (7.1)	8 (4.7)	8 (7.3)	10 (5.3)	17 (7.0)	28 (10.9)	21 (6.8)	15 (7.7)
Metabolic (excluding NAFLD)	4 (2.2)	2 (1.1)	1 (0.6)	3 (2.7)	1 (0.5)	2 (0.8)	3 (1.2)	4 (1.3)	1 (0.5)
Other	0 (0)	6 (3.3)	8 (4.7)	4 (3.6)	11 (5.8)	9 (3.7)	16 (6.2)	24 (7.7)	20 (10.3)
Retransplant	3 (1.6)	5 (2.7)	3 (1.8)	7 (6.4)	6 (3.2)	4 (1.6)	8 (3.1)	10 (3.2)	10 (5.1)
<b>Zonal Transplants</b>									
Non zonal	65 (34.9)	75 (41.2)	65 (38.2)	42 (38.2)	77 (40.7)	86 (35.4)	72 (28.0)	124 (40.0)	67 (34.4)
Zonal	121 (65.1)	107 (58.8)	105 (61.8)	68 (61.8)	112 (59.3)	157 (64.6)	185 (72.0)	186 (60.0)	128 (65.6)
<b>Blood group matching (D=donor, R=recipient)</b>									
DO, RO	95 (51.1)	79 (43.4)	68 (40.0)	52 (47.3)	88 (46.6)	115 (47.3)	125 (48.6)	128 (41.3)	98 (50.5)
DO, RA	0 (0)	0 (0)	3 (1.8)	1 (0.9)	4 (2.1)	2 (0.8)	0 (0)	5 (1.6)	1 (0.5)
DO, RB	0 (0)	5 (2.7)	5 (2.9)	0 (0)	2 (1.1)	6 (2.5)	5 (1.9)	1 (0.3)	1 (0.5)
DO, RAB	0 (0)	1 (0.5)	0 (0)	0 (0)	1 (0.5)	0 (0)	0 (0)	0 (0)	0 (0)
DA, RA	70 (37.6)	75 (41.2)	77 (45.3)	48 (43.6)	73 (38.6)	88 (36.2)	94 (36.6)	134 (43.2)	78 (40.2)
DA, RAB	1 (0.5)	1 (0.5)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	2 (0.6)	0 (0)
DB, RB	18 (9.7)	16 (8.8)	13 (7.6)	7 (6.4)	21 (11.1)	27 (11.1)	28 (10.9)	32 (10.3)	15 (7.7)
DB, RAB	0 (0)	0 (0)	1 (0.6)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)
DAB, RAB	2 (1.1)	5 (2.7)	3 (1.8)	2 (1.8)	0 (0)	4 (1.6)	4 (1.6)	8 (2.6)	1 (0.5)

\*1 transplant performed with unknown donor blood group in 2025/26

3.5.5. **Table 17(a&b)** and **Table 18(a&b)** show the median waiting time to transplant for the adult elective transplants performed in the UK by transplant centre, blood group and type of patient, for DBD and DCD transplants respectfully. Overall, the median time to transplant was statistically significantly different across the time periods of interest for both DBD and DCD transplants (both with a Kruskal-Wallis p-value<0.0001).

**Table 17a Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 September 2025, as at 10 October 2025**

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*
<b>Overall (N)</b>	<b>635</b>	<b>621</b>	<b>607</b>	<b>476</b>	<b>481</b>	<b>449</b>	<b>452</b>	<b>415</b>	<b>211</b>
Median (IQR)	71 (23, 198)	39 (10, 138)	43 (10, 144)	42.5 (9, 161.5)	33 (9, 105)	40 (9, 156)	58 (14, 192)	59 (14, 198)	42 (8, 128)
Range	0 - 1835	1 - 1711	0 - 1620	0 - 1814	0 - 1470	117975	1 - 1420	1 - 1647	0 - 1780
<b>Type of patient</b>									
CLD (N)	477	485	471	398	401	362	338	313	161
Median (IQR)	65 (20, 186)	30 (8, 96)	25 (8, 93)	31.5 (8, 136)	25 (8, 82)	28.5 (8, 123)	40 (12, 147)	41 (12, 159)	30 (7, 105)
Range	0 - 1519	1 - 1518	0 - 1450	0 - 1814	0 - 1470	117975	1 - 915	1 - 1556	1 - 1474
HCC (N)	104	72	80	54	39	45	57	44	20
Median (IQR)	57 (23, 184)	55 (22.5, 145)	79 (33.5, 167.5)	62 (24, 128)	53 (21, 107)	77 (27, 179)	109 (40, 238)	79.5 (31, 163)	48 (22, 118)
Range	2 - 1030	1 - 568	1 - 739	0 - 664	2 - 1400	1 - 769	8 - 1420	3 - 1004	0 - 567
VS (N)	49	59	51	21	28	29	35	36	18
Median (IQR)	187 (79, 543)	296 (100, 836)	365 (174, 613)	367 (261, 585)	385 (200, 612)	570 (264, 880)	369 (129, 833)	294.5 (166, 599)	217.5 (105, 647)
Range	2 - 1835	2 - 1711	16 - 1620	3 - 1260	17 - 1326	20 - 2100	5 - 1401	10 - 1300	5 - 1780
ACLF (N)	0	0	0	0	10	13	21	22	11
Median (IQR)	-	-	-	-	11.5 (5, 42)	10 (7, 63)	12 (4, 46)	7.5 (3, 169)	74 (7, 402)
Range	-	-	-	-	2 - 968	2 - 1014	1 - 333	2 - 1647	2 - 1321
HCC downstaging (N)	5	5	5	3	3	0	1	0	1
Median (IQR)	93 (63, 131)	14 (10, 27)	58 (22, 128)	44 (4, 240)	42 (31, 115)	-	71 (-)	-	74 (-)
Range	16 - 384	6 - 65	17 - 204	4 - 240	31 - 115	-	-	-	-

\*Six months included, up to 19 September 2025

**Table 17b Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 September 2025, as at 10 October 2025**

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*
<b>Centre</b>									
Newcastle (N)	30	22	26	27	23	14	17	21	5
Median (IQR)	47 (17, 111)	43 (17, 96)	28.5 (14, 85)	43 (9, 190)	45 (13, 110)	8.5 (5, 45)	22 (12, 164)	30 (8, 78)	4 (2, 18)
Range	1 - 377	2 - 318	1 - 517	2 - 607	2 - 760	4 - 998	4 - 1233	3 - 485	2 - 31
Leeds (N)	108	66	79	70	60	74	71	79	35
Median (IQR)	64.5 (26, 228.5)	41.5 (9, 145)	33 (9, 136)	52.5 (14, 159)	27.5 (9, 113)	22.5 (7, 133)	41 (12, 137)	74 (15, 180)	54 (12, 113)
Range	1 - 1402	1 - 1341	1 - 1405	1 - 1260	1 - 1187	1 - 1058	1 - 873	2 - 1454	2 - 1780
Cambridge (N)	71	65	60	35	50	40	52	45	20
Median (IQR)	74 (21, 200)	36 (10, 88)	17 (8.5, 67)	23 (9, 76)	37 (9, 90)	15 (7, 62.5)	20 (7, 73.5)	27 (6, 80)	19 (6.5, 88.5)
Range	0 - 1343	1 - 760	1 - 656	0 - 679	0 - 633	1 - 407	1 - 753	2 - 1285	2 - 1031
Royal Free (N)	84	83	91	57	65	68	68	73	35
Median (IQR)	99.5 (29.5, 236.5)	33 (7, 133)	37 (11, 96)	37 (8, 79)	28 (8, 154)	50 (11, 141)	54 (14.5, 234)	45 (11, 197)	30 (10, 95)
Range	0 - 945	1 - 1261	1 - 971	0 - 669	2 - 592	2 - 1453	2 - 1004	1 - 985	1 - 316
Kings College (N)	128	143	145	115	117	98	103	83	56
Median (IQR)	125 (45, 374)	54 (11, 252)	54 (11, 164)	32 (8, 140)	33 (9, 98)	85.5 (11, 288)	93 (26, 265)	83 (21, 319)	43.5 (8.5, 200.5)
Range	1 - 1813	1 - 1711	1 - 1620	0 - 1687	1 - 968	2 - 2100	1 - 1286	1 - 1647	0 - 801
Birmingham (N)	133	154	154	114	127	115	110	79	44
Median (IQR)	48 (15, 137)	42.5 (11, 105)	58.5 (9, 204)	71.5 (8, 262)	34 (9, 146)	65 (16, 286)	89 (22, 235)	95 (16, 333)	121.5 (7.5, 280.5)
Range	0 - 1519	1 - 1657	0 - 976	1 - 1814	1 - 1470	1 - 2223	1 - 1420	1 - 1556	2 - 1474
Edinburgh (N)	81	88	52	58	39	40	31	35	16
Median (IQR)	42 (12, 109)	24.5 (6, 115.5)	46.5 (19, 140)	45.5 (9, 239)	17 (7, 39)	22.5 (8, 58)	76 (30, 191)	31 (16, 136)	37 (11, 69)
Range	0 - 1835	1 - 1124	2 - 640	1 - 749	1 - 452	2 - 218	3 - 1401	2 - 1274	1 - 988
<b>Recipient blood group</b>									
O (N)	298	294	262	182	171	156	212	168	89
Median (IQR)	113.5 (32, 280)	60 (14, 218)	56.5 (12, 188)	52.5 (11, 216)	37 (10, 132)	58 (11.5, 204)	60.5 (13, 228.5)	58 (14, 198.5)	37 (8, 122)
Range	0 - 1835	1 - 1711	1 - 1620	0 - 1814	0 - 1470	1 - 1453	1 - 1420	1 - 1454	1 - 1780
A (N)	246	235	238	208	221	224	163	173	90
Median (IQR)	40 (16, 93)	23 (7, 77)	33 (9, 100)	27 (7, 138)	27 (8, 100)	30 (9, 148)	61 (14, 181)	56 (12, 197)	43 (7, 138)
Range	0 - 1109	1 - 1056	0 - 758	0 - 786	1 - 918	1 - 2223	2 - 1004	1 - 985	0 - 1321
B (N)	71	56	64	60	57	49	53	52	20
Median (IQR)	168 (49, 384)	57 (15, 132)	66 (18.5, 167.5)	66 (21.5, 279.5)	33 (9, 103)	50 (23, 173)	64 (31, 162)	79 (30.5, 279)	89.5 (40, 358.5)
Range	0 - 1813	2 - 1518	2 - 865	2 - 1335	2 - 592	2 - 2100	1 - 1233	2 - 1647	4 - 1324
AB (N)	20	36	43	26	32	20	24	22	12
Median (IQR)	25.5 (7.5, 66)	39.5 (13, 93)	19 (4, 43)	27 (13, 78)	24 (8, 57)	11 (5.5, 25.5)	32.5 (15, 73.5)	41 (5, 79)	18.5 (6.5, 51.5)
Range	0 - 148	1 - 466	1 - 201	5 - 340	2 - 388	1 - 63	2 - 302	2 - 1556	4 - 126

\*Six months included, up to 19 September 2025

**Table 18a Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2025, as at 10 October 2025**

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*
<b>Overall (N)</b>	<b>186</b>	<b>182</b>	<b>170</b>	<b>110</b>	<b>189</b>	<b>243</b>	<b>257</b>	<b>310</b>	<b>195</b>
<b>Median (IQR)</b>	<b>41.5 (14, 142)</b>	<b>53 (20, 128)</b>	<b>52 (19, 142)</b>	<b>90.5 (29, 205)</b>	<b>98 (38, 163)</b>	<b>132 (50, 306)</b>	<b>137 (43, 294)</b>	<b>133.5 (49, 340)</b>	<b>148 (41, 319)</b>
<b>Range</b>	<b>0 - 875</b>	<b>0 - 607</b>	<b>2 - 693</b>	<b>2 - 1278</b>	<b>1 - 923</b>	<b>1 - 1242</b>	<b>1 - 1395</b>	<b>0 - 2358</b>	<b>1 - 2918</b>
<b>Type of patient</b>									
CLD (N)	123	87	107	72	104	145	164	205	132
Median (IQR)	41 (13, 143)	55 (19, 125)	50 (15, 147)	104.5 (35.5,205.5)	102 (29.5, 178)	139 (49, 328)	143.5 (50, 309)	178 (62, 360)	156.5 (48, 329)
Range	0 - 875	0 - 561	2 - 693	2 - 1101	1 - 923	1 - 1242	1 - 1395	0 - 2358	2 - 2216
HCC (N)	52	83	58	33	73	84	75	81	47
Median (IQR)	39.5 (16.5,110)	49 (20, 148)	66.5 (35, 135)	73 (29, 144)	95 (45, 157)	122 (47, 269.5)	110 (29, 244)	96 (42, 201)	109 (28, 255)
Range	1 - 691	2 - 607	4 - 322	5 - 1278	2 - 822	2 - 868	2 - 787	3 - 1187	1 - 858
VS (N)	9	5	1	2	8	12	13	17	13
Median (IQR)	222 (32, 347)	98 (72, 300)	559 (559, 559)	218 (215, 221)	154 (103.5,254.5)	191.5 (68, 238)	163 (79, 381)	453 (83, 691)	239 (94, 371)
Range	7 - 870	5 - 306	559 - 559	215 - 221	70 - 396	51 - 636	25 - 905	4 - 1067	26 - 2918
ACLF (N)	0	0	0	0	1	0	1	1	0
Median (IQR)	-	-	-	-	2 (-)	-	1 (-)	5 (-)	-
Range	-	-	-	-	2	-	1	5	-
HCC downstaging (N)	2	7	4	3	3	2	4	6	3
Median (IQR)	53 (51, 55)	47 (17, 84)	21 (12, 35.5)	72 (27, 216)	52 (24, 143)	102.5 (94, 111)	70.5 (12.5,200)	59.5 (24, 103)	40 (12, 62)
Range	51 - 55	11 - 323	12 - 41	27 - 216	24 - 143	94 - 111	8 - 276	22 - 135	12 - 62



**Table 18b Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 September 2025, as at 10 October 2025**



	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*
<b>Centre</b>									
Newcastle (N)	5	3	4	2	13	14	25	19	6
Median (IQR)	106 (85, 304)	304 (22, 452)	144.5 (119,371)	110 (4, 216)	152 (117, 394)	173 (47, 247)	42 (24, 137)	42 (6, 65)	105.5 (15, 229)
Range	5 - 347	22 - 452	103 - 588	4 - 216	5 - 817	26 - 770	2 - 1169	3 - 187	5 - 250
Leeds (N)	26	21	21	15	16	26	36	17	19
Median (IQR)	77.5 (13, 297)	36 (12, 99)	36 (12, 73)	56 (26, 133)	115.5 (52, 147)	118.5 (46, 362)	234 (72, 501.5)	209 (116, 427)	89 (30, 210)
Range	0 - 875	2 - 517	2 - 565	5 - 511	4 - 923	13 - 868	1 - 1128	24 - 893	12 - 522
Cambridge (N)	32	40	33	35	48	53	51	59	34
Median (IQR)	60 (28.5, 151.5)	57.5 (21.5, 128)	35 (14, 78)	89 (46, 211)	63 (21.5, 142.5)	111 (29, 210)	76 (43, 213)	108 (41, 287)	88 (37, 171)
Range	0 - 870	2 - 355	2 - 479	5 - 625	1 - 822	2 - 832	6 - 779	0 - 1111	3 - 759
Royal Free (N)	13	28	37	11	23	18	30	45	27
Median (IQR)	62 (24, 234)	56.5 (29.5, 144)	55 (23, 135)	57 (23, 205)	94 (27, 148)	139.5 (67, 388)	53.5 (20, 136)	96 (37, 155)	105 (13, 160)
Range	3 - 369	2 - 323	4 - 693	11 - 227	8 - 327	5 - 911	3 - 740	3 - 2358	2 - 1007
Kings College (N)	46	38	37	31	46	51	49	60	56
Median (IQR)	67 (27, 205)	72.5 (34, 180)	84 (38, 198)	123 (54, 189)	133.5 (52, 162)	198 (92, 341)	190 (94, 375)	215 (114.5, 354)	243.5(92.5,393.5)
Range	4 - 691	4 - 607	3 - 559	8 - 1101	1 - 342	1 - 716	1 - 1093	5 - 1067	5 - 2918
Birmingham (N)	52	39	33	11	25	54	34	85	37
Median (IQR)	22.5 (13, 42.5)	34 (14, 80)	50 (30, 125)	115 (7, 221)	94 (60, 218)	111 (42, 258)	145 (69, 381)	238 (46, 409)	198 (124, 858)
Range	0 - 511	0 - 487	2 - 267	2 - 259	12 - 418	2 - 1039	1 - 987	3 - 1187	1 - 2216
Edinburgh (N)	12	13	5	5	18	27	32	25	16
Median (IQR)	41.5 (10, 94.5)	71 (38, 333)	51 (44, 151)	42 (30, 777)	52.5 (16, 151)	137 (38, 471)	228 (44, 304.5)	116 (58, 350)	143.5(30.5,316.5)
Range	0 - 783	6 - 383	40 - 224	27 - 1278	2 - 738	2 - 1242	4 - 1395	29 - 1435	14 - 778
<b>Recipient blood group</b>									
O (N)	95	79	68	52	88	115	125	128	98
Median (IQR)	62 (16, 245)	69 (28, 175)	69 (19, 163.5)	115.5 (28, 222)	117 (45.5, 182.5)	158 (75, 355)	170 (56, 334)	189 (61.5, 389)	168.5 (75, 423)
Range	0 - 875	0 - 561	2 - 693	7 - 1278	1 - 822	2 - 1242	1 - 1169	3 - 1435	2 - 2918
A (N)	70	75	80	49	77	90	94	139	79
Median (IQR)	29 (10, 65)	37 (17, 78)	50 (19, 100.5)	78 (26, 189)	93 (28, 143)	104.5 (42, 236)	114 (39, 272)	116 (41, 325)	102 (22, 238)
Range	0 - 351	2 - 457	2 - 588	2 - 530	2 - 476	2 - 911	1 - 1395	0 - 2358	1 - 1745
B (N)	18	21	18	7	23	33	33	33	16
Median (IQR)	55 (19, 262)	103 (30, 171)	87 (43, 183)	92 (57, 119)	86 (40, 271)	147 (64, 243)	67 (38, 277)	145 (83, 266)	190 (42.5, 368)
Range	4 - 783	4 - 607	2 - 479	29 - 446	1 - 923	4 - 868	6 - 787	17 - 1007	11 - 914
AB (N)	3	7	4	2	1	5	5	10	2
Median (IQR)	27 (9, 111)	23 (9, 94)	7.5 (6.5, 22)	60.5 (48, 73)	77 (77, 77)	2 (2, 41)	14 (9, 22)	55.5 (11, 74)	52 (17, 87)
Range	9 - 111	6 - 111	6 - 36	48 - 73	77 - 77	1 - 60	1 - 79	3 - 132	17 - 87

\*Six months included, up to 19 September 2025

3.5.6. **Figure 16** shows the overall cold ischaemia time for the time periods of interest for DBD transplants while **Figure 17** shows the cold ischaemia time for each centre. **Figures 18** and **Figure 19** show the equivalent information for DCD donor transplants.

3.5.7. There were statistically significant differences in the cold ischaemia time for adult elective DBD and DCD transplants over the time periods of interest ( $p=0.004$  for DBD and  $p<0.001$  for DCD). However, it should be noted that these results will change as NHTSB has not received all the first week transplant record forms which collect the cold ischaemia time. It should also be noted that this analysis does not adjust for whether machine perfusion was used.






### 3.6. NINETY-DAY POST-TRANSPLANT SURVIVAL

3.6.1. **Figure 20** shows the unadjusted ninety-day patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first eighty-seven months of NLOS. **Table 20a** and **Table 20b** shows the survival estimates and confidence intervals by blood group and type of patient for DBD and DCD transplants respectively. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.

3.6.2. For DBD transplants, there was no overall statistically significant difference between the time periods of interest in ninety-day patient survival (log-rank p-value=0.43). There was a borderline statistically significant difference in ninety-day survival for CLD patients (log-rank p-value=0.05) and HCC patients (log-rank p-value=0.03). There were no statistically significant differences between the time periods for the individual centres (log-rank p-value $\geq$ 0.15) and blood groups (log-rank p-value $\geq$ 0.41), apart from blood group B patients which had significance (p=0.03).

3.6.3. For DCD transplants, there was no overall statistically significant difference at a 5% significance level overall between the time periods in ninety-day patient survival (log-rank p-value=0.10). There were no statistically significant differences between the time periods for CLD and HCC (log rank p-value $\geq$ 0.09) and blood groups (log rank p-value $\geq$ 0.44). There were no statistical significant differences between the time periods for the individual centres (log rank p-value $\geq$ 0.13).

**Figure 20 Unadjusted ninety day patient survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 June 2025**



**Table 19 Median hospital stay post-transplant for adult elective liver and liver/kidney transplants performed in the UK using livers from deceased donors, 20 March 2017 to 19 June 2025, as at 10 October 2025**

	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026*
<b>DBD</b>									
N	579	567	555	420	454	418	426	379	95
No. (%) with discharge date reported	542 (94)	524 (92)	530 (95)	401 (95)	433 (95)	389 (93)	398 (93)	362 (96)	85 (89)
Median (range) time from transplant to hospital discharge	14 (10 - 20)	13 (10 - 18)	13 (10 - 19)	14 (11 - 21)	15 (11 - 23)	14 (10 - 21)	14 (11 - 23)	15 (11 - 24)	13 (10 - 20)
No. (%) with no discharge date but a death date reported	23 (4)	24 (4.2)	13 (2.3)	12 (2.9)	11 (2.4)	16 (3.8)	14 (3.3)	6 (1.6)	3 (3.2)
Median (range) time from tx to death date	32 (14 - 62)	52 (7 - 194)	41 (2 - 181)	18 (8.5-48.5)	30 (2 - 85)	32.5 (14.5-141.5)	46 (9 - 58)	20.5 (4 - 26)	25 (3 - 62)
No. (%) with no discharge or death date reported	14 (2.4)	19 (3.4)	12 (2.2)	7 (1.7)	10 (2.2)	13 (3.1)	14 (3.3)	11 (2.9)	7 (7.4)
<b>DCD</b>									
N	183	177	166	103	183	239	249	300	73
No. (%) with discharge date reported	176 (96)	160 (90)	151 (91)	98 (95)	169 (92)	223 (93)	233 (94)	278 (93)	71 (97)
Median (range) time from transplant to hospital discharge	12.5 (9 - 17)	14 (10 - 19)	13 (9 - 20)	14 (10 - 19)	14 (10 - 20)	13 (10 - 21)	15 (11 - 22)	13 (10 - 19)	13 (9 - 20)
No. (%) with no discharge date but a death date reported	4 (2.2)	10 (5.6)	10 (6)	3 (2.9)	6 (3.3)	6 (2.5)	9 (3.6)	10 (3.3)	0 (0)
Median (range) time from tx to death date	44.5 (5 - 1278.5)	23.5 (4 - 190)	27 (1 - 45)	119 (52 - 1382)	105.5 (38 - 183)	35 (19 - 77)	25 (8 - 139)	20.5 (1 - 43)	-
No. (%) with no discharge or death date reported	3 (1.6)	7 (4)	5 (3)	2 (1.9)	8 (4.4)	10 (4.2)	7 (2.8)	12 (4)	2 (2.7)

\*includes transplants up to 19 June 2025

**Table 20a** 90-day patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 June 2025

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*	Log-rank p-value
<b>Overall (No at risk)</b>	<b>579</b>	<b>567</b>	<b>555</b>	<b>420</b>	<b>454</b>	<b>418</b>	<b>426</b>	<b>275</b>	<b>379</b>	0.4253
% (95% CI)	96.2 (94.3,97.5)	96.5 (94.6,97.7)	98.2 (96.7,99.0)	97.1 (95.0,98.4)	97.8 (95.9,98.8)	96.9 (94.7,98.2)	97.2 (95.1,98.4)	98.2 (95.6,99.2)	98.4 (96.5,99.3)	
<b>Type of patient</b>										
CLD (No at risk)	425	436	423	346	375	333	313	279	73	0.0467
% (95% CI)	95.5 (93.1,97.1)	95.9 (93.5,97.4)	98.1 (96.3,99)	98.3 (96.2,99.2)	98.1 (96.1,99.1)	97.9 (95.6,99)	98.1 (95.8,99.1)	98.5 (96.2,99.5)	98.6 (90.7,99.8)	
HCC (No at risk)	104	71	80	53	39	45	57	44	8	0.0289
% (95% CI)	98.1 (92.5,99.5)	97.2 (89.2,99.3)	98.8 (91.5,99.8)	90.6 (78.8,96)	97.4 (83.2,99.6)	88.9 (75.3,95.2)	96.5 (86.7,99.1)	100 (-)	100 (-)	
VS (No at risk)	45	55	47	18	27	27	34	35	8	0.3099
% (95% CI)	97.8 (85.3,99.7)	100 (-)	97.9 (85.8,99.7)	94.4 (66.6,99.2)	96.3 (76.5,99.5)	100 (-)	97.1 (80.9,99.6)	100 (-)	87.5 (38.7,98.1)	
HCC downstaging (No at risk)	5	5	5	3	3	0	1	0	1	-
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	-	100 (-)	-	100 (-)	
ACLF (No at risk)	0	0	0	0	10	13	21	21	5	0.9408
% (95% CI)	-	-	-	-	90 (47.3,98.5)	92.3 (56.6,98.9)	85.7 (62.0,95.2)	90.5 (67,97.5)	80 (20.4,96.9)	
<b>Recipient blood group</b>										
O (No at risk)	272	266	241	162	162	149	195	152	45	0.4056
% (95% CI)	95.2 (91.9,97.2)	97.4 (94.6,98.7)	98.8 (96.2,99.6)	97.5 (93.6,99.1)	97.5 (93.6,99.1)	97.3 (93.0,99.0)	97.9 (94.6,99.2)	98.7 (94.8,99.7)	97.8 (85.3,99.7)	
A (No at risk)	224	214	215	182	205	205	160	158	38	0.7007
% (95% CI)	96.4 (93.0,98.2)	96.3 (92.7,98.1)	97.7 (94.5,99.0)	96.2 (92.1,98.1)	98 (94.9,99.3)	98 (94.9,99.3)	97.5 (93.5,99.1)	98.7 (95,99.7)	94.7 (80.6,98.7)	
B (No at risk)	66	53	59	52	55	45	51	49	7	0.0278

% (95% CI)	100 (-)	92.5 (81.1,97.1)	98.3 (88.6,99.8)	98.1 (87.1,99.7)	100 (-)	88.9 (75.3,95.2)	94.1 (82.9,98.1)	98 (86.4,99.7)	100 (-)	
AB (No at risk)	17	34	40	24	32	19	20	20	5	0.9117
% (95% CI)	94.1 (65.0,99.1)	97.1 (80.9,99.6)	97.5 (83.5,99.6)	100 (-)	93.8 (77.3,98.4)	100 (-)	95 (69.5,99.3)	95 (69.5,99.3)	100 (-)	
<b>Centre</b>										
Newcastle (No at risk)	26	22	24	24	23	13	17	20	3	0.5884
% (95% CI)	92.3 (72.6,98.0)	95.5 (71.9,99.3)	95.8 (73.9,99.4)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	
Leeds (No at risk)	101	59	73	63	60	68	65	73	15	0.4827
% (95% CI)	93.1 (86.96.6)	91.5 (80.8,96.4)	98.6 (90.7,99.8)	95.2 (86.0,98.4)	95 (85.3,98.4)	97.1 (88.7,99.3)	93.8 (84.4,97.6)	98.6 (90.7,99.8)	93.3 (61.3,99)	
Cambridge (No at risk)	67	61	58	28	50	39	52	44	7	0.3894
% (95% CI)	97 (88.6,99.2)	100 (-)	94.8 (84.8,98.3)	100 (-)	100 (-)	100 (-)	96.2 (85.5,99.0)	95.5 (83.98.8)	100 (-)	
Royal Free (No at risk)	82	80	88	50	61	64	65	70	17	0.3038
% (95% CI)	96.3 (89.1,98.8)	93.8 (85.6,97.3)	100 (-)	98 (86.6,99.7)	96.7 (87.5,99.2)	96.9 (88.1,99.2)	96.9 (88.3,99.2)	100 (-)	100 (-)	
Kings College (No at risk)	111	128	132	104	110	88	95	70	27	0.8334
% (95% CI)	98.2 (92.9,99.5)	99.2 (94.6,99.9)	98.5 (94.1,99.6)	99 (93.4,99.9)	98.2 (92.9,99.5)	100 (-)	98.9 (92.8,99.9)	97.1 (88.7,99.3)	96.3 (76.5,99.5)	
Birmingham (No at risk)	117	133	135	96	113	108	102	70	18	0.3841
% (95% CI)	95.7 (90.0,98.2)	96.2 (91.2,98.4)	99.3 (94.9,99.9)	95.8 (89.3,98.4)	97.3 (92.9,99.1)	96.3 (90.4,98.6)	99 (93.2,99.9)	100 (-)	94.4 (66.6,99.2)	
Edinburgh (No at risk)	75	84	45	55	37	38	30	32	8	0.146
% (95% CI)	98.7 (90.9,99.8)	96.4 (89.3,98.8)	95.6 (83.4,98.9)	94.5 (84.0,98.2)	100 (-)	86.8 (71.2,94.3)	93.3 (75.9,98.3)	96.9 (79.8,99.6)	100 (-)	

\*20 March 2025 – 19 June 2025

**Table 20b** 90-day patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 June 2025


	2017/18 183	2018/19 177	2019/20 166	2020/21 103	2021/22 183	2022/23 239	2023/24 249	2024/25 300	2025/26* 73	Log-rank 0.101
<b>Overall (No at risk)</b>	<b>98.4</b> <b>(95.0,99.5)</b>	<b>94.9</b> <b>(90.5,97.3)</b>	<b>94.6</b> <b>(89.8,97.1)</b>	<b>98</b> <b>(92.4,99.5)</b>	<b>98.4</b> <b>(95.0,99.5)</b>	<b>97.9</b> <b>(95.0,99.1)</b>	<b>97.6</b> <b>(94.7,98.9)</b>	<b>95.9</b> <b>(93.97.7)</b>	<b>100</b> <b>(-)</b>	
<b>Type of patient</b>										
CLD (No at risk)	120	83	103	65	98	141	157	195	56	0.4167
% (95% CI)	98.3 (93.5,99.6)	95.2 (87.7,98.2)	97.1 (91.2,99.1)	98.5 (89.6,99.8)	99 (93.0,99.9)	98.6 (94.4,99.6)	98.1 (94.2,99.4)	95.8 (91.8,97.9)	100 (-)	
HCC (No at risk)	52	83	58	33	73	84	75	81	13	0.0851
% (95% CI)	98.1 (87.1,99.7)	95.2 (87.7,98.2)	89.7 (78.4,95.2)	97 (80.4,99.6)	100 (-)	97.6 (90.8,99.4)	97.3 (89.8,99.3)	97.5 (90.5,99.4)	100 (-)	
VS (No at risk)	9	4	1	2	8 87.5	12 91.7	12	17 94.1	2	0.9224
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	(38.7,98.1)	(53.9,98.8)	100 (-)	(65,99.1)	100 (-)	
HCC downstaging (No at risk)	2	7 85.7	4	3	3	2	4 75	6 83.3	2	0.9034
% (95% CI)	100 (-)	(33.4,97.9)	100 (-)	100 (-)	100 (-)	100 (-)	(12.8,96.1)	(27.3,97.5)	100 (-)	
ACLF (No at risk)	0	0	0	0	1 0 (-)	0 -	1 100 (-)	1 100 (-)	0	0.3679
% (95% CI)	-	-	-	-	0 (-)	-	100 (-)	100 (-)	-	
<b>Recipient blood group</b>										
O (No at risk)	95	78	67	48	86	111	119	124	35	0.4363
% (95% CI)	97.9 (91.8,99.5)	93.6 (85.3,97.3)	94 (84.9,97.7)	95.7 (84.0,98.9)	98.8 (92.0,99.8)	98.2 (93.0,99.5)	96.6 (91.3,98.7)	96.8 (91.6,98.8)	100 (-)	
A (No at risk)	67	72	78	46	74 97.3	90 97.8	92 98.9	133 96.1	31	0.5603
% (95% CI)	98.5 (89.9,99.8)	98.6 (90.5,99.8)	94.9 (86.9,98.0)	100 (-)	(89.6,99.3)	(91.4,99.4)	(92.5,99.8)	(90.9,98.4)	100 (-)	
B (No at risk)	18	20	18	7	22	33	33	33	5	0.7299

% (95% CI)	100 (-)	90 (65.6,97.4)	94.4 (66.6,99.2)	100 (-)	100 (-)	97 (80.4,99.6)	97 (80.4,99.6)	97 (80.4,99.6)	100 (-)	
AB (No at risk)	3	7 85.7	3	2	1	5	5	10 80	2	0.8441
% (95% CI)	100 (-)	(33.4,97.9)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	(40.9,94.6)	100 (-)	
<b>Centre</b>										
Newcastle (No at risk)	4	3	4	2	13	14 92.9	25	18	4	0.7344
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	(59.1,99.0)	100 (-)	100 (-)	100 (-)	
Leeds (No at risk)	26 96.2	20 95	21 90.5	15	16	26	35 88.6	17 94.1	8	0.4768
% (95% CI)	(75.7,99.4)	(69.5,99.3)	(67,97.5)	100 (-)	100 (-)	100 (-)	(72.4,95.5)	(65,99.1)	100 (-)	
Cambridge (No risk)	30 96.7	37 97.3	31 93.5	29	43 95.3	52 98.1	47	57 96.5	11	0.7507
% (95% CI)	(78.6,99.5)	(82.3,99.6)	(76.6,98.3)	100 (-)	(82.7,98.8)	(87.1,99.7)	100 (-)	(86.7,99.1)	100 (-)	
Royal Free (No risk)	13	28 92.9	36 94.4	11 81.8	22	18 88.9	30 96.7	44 95.4	10	0.4484
% (95% CI)	100 (-)	(74.3,98.2)	(79.6,98.6)	(44.7,95.1)	100 (-)	(62.4,97.1)	(78.6,99.5)	(82.8,98.8)	100 (-)	
Kings College (No at risk)	46	37 94.6	36 97.2	30	46	48 97.9	46	59 98.3	14	0.4593
% (95% CI)	100 (-)	(80.1,98.6)	(81.9,99.6)	100 (-)	100 (-)	(86.1,99.7)	100 (-)	(88.6,99.8)	100 (-)	
Birmingham (No at risk)	52 98.1	39 92.3	33 97	11	25	54	34 97.1	82 95.1	15	0.4660
% (95% CI)	(87.1,99.7)	(78.0,97.5)	(80.4,99.6)	100 (-)	100 (-)	100 (-)	(80.9,99.6)	(87.5,98.1)	100 (-)	
Edinburgh (No at risk)	12	13	5 80	5	18 94.4	27	32	23 91.3	11	0.1258
% (95% CI)	100 (-)	100 (-)	(20.4,96.9)	100 (-)	(66.6,99.2)	100 (-)	100 (-)	(69.5,97.8)	100 (-)	
*20 March 2025 – 19 June 2025										

3.6.4. **Figure 21** shows the unadjusted ninety-day transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first eighty-seven months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 90 days.

3.6.5. There were no statistically significant differences in the unadjusted ninety-day transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.62 and 0.47).

**Figure 21 Unadjusted ninety day transplant survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 June 2025**




### 3.8 ONE-YEAR POST-TRANSPLANT SURVIVAL

3.8.1 **Figure 22** shows the unadjusted one-year patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first sevnty-eighth months of NLOS. **Table 21** and **Table 22** shows the survival estimates and confidence intervals by blood group and type of patient, for DBD and DCD transplants respectively. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.

3.8.2 For DBD transplants, there was no overall statistically significant difference between the time periods of interest in one-year patient survival (log-rank p-value=0.53). There were no statistically significant difference between the two time periods for CLD and HCC (log rank p-value $\geq$ 0.82), for the individual centres (log-rank p-value $\geq$ 0.09) or the recipient blood groups (log rank p-value $\geq$ 0.06).

3.8.3 For DCD transplants, there was no overall statistically significant difference at a 5% significance level overall between the time periods in one-year patient survival (log-rank p-value=0.59). There were no statistically significant differences between the two time periods for CLD and HCC (log rank p-value $\geq$ 0.40), blood groups (log rank p-value $\geq$ 0.41) and for the individual centres (log rank p-value $\geq$ 0.27).

**Figure 22 Unadjusted one year patient survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 September 2024**



**Table 21a** 1-year patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 September 2024

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25*	Log-rank p-value
<b>Overall (No at risk)</b>	579	567	555	420	454	418	426	192	0.5283
% (95% CI)	94.6 (92.5,96.2)	94.5 (92.3,96.1)	96.0 (94.0,97.4)	96.4 (94.1,97.8)	94.9 (92.4,96.6)	93.7 (90.9,95.7)	95.2 (92.7,96.9)	97.2 (93.3,98.8)	
<b>Type of patient</b>									
CLD (No at risk)	425	436	423	346	375	333	313	145	0.1215
% (95% CI)	93.9 (91.1,95.8)	94.5 (91.9,96.3)	96.7 (94.5,98.0)	97.4 (95.0,98.6)	95.4 (92.8,97.1)	94.6 (91.5,96.5)	96.1 (93.2,97.8)	98.6 (94.5,99.6)	
HCC (No at risk)	104	71	80	53	39	45	57	17	0.8236
% (95% CI)	96.1 (89.9,98.5)	93.0 (83.9,97.0)	93.8 (85.6,97.3)	90.6 (78.8,96.0)	92.3 (78.0,97.5)	88.9 (75.3,95.2)	92.7 (81.7,97.2)	90 (47.3,98.5)	
VS (No at risk)	45	55	47	18	27	27	34	20	0.9557
% (95% CI)	97.8 (85.3,99.7)	96.3 (86.1,99.1)	93.6 (81.5,97.9)	94.4 (66.6,99.2)	96.3 (76.5,99.5)	96.3 (76.5,99.5)	97.1 (80.9,99.6)	100 (-)	.
HCC downstaging (No at risk)	5	5	5	3	3	0	1	0	-
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	-	100 (-)	-	
<b>Recipient blood group</b>									
O (No at risk)	272	266	241	162	162	149	195	78	0.4542
% (95% CI)	93.7 (90.1,96.1)	94 (90.3,96.3)	96.7 (93.4,98.3)	96.9 (92.7,98.7)	95 (90.3,97.5)	93.9 (88.6,96.8)	95.8 (91.8,97.9)	98.7 (91.2,99.8)	
A (No at risk)	224	214	215	182	205	205	160	79	0.986
% (95% CI)	95.1 (91.3,97.3)	95.8 (92.1,97.8)	94.9 (90.9,97.1)	95 (90.7,97.4)	95.1 (91.1,97.3)	95.1 (91.0,97.3)	96.8 (92.6,98.7)	96.9 (87.9,99.2)	

B (No at risk)	66	53	59	52	55	45	51	26	0.058
% (95% CI)	97.0 (88.4,99.2)	92.5 (81.1,97.1)	96.6 (87.1,99.1)	98.1 (87.1,99.7)	98.1 (87.4,99.7)	86.6 (72.6,93.8)	87.9 (75.94.4)	96.2 (75.7,99.4)	
AB (No at risk)	17	34	40	24	32	19	20	9	0.5796
% (95% CI)	94.1 (65.0,99.1)	94.0 (78.2,98.5)	97.5 (83.5,99.6)	100 (-)	87.5 (70.0,95.1)	94.7 (68.1,99.2)	95 (69.5,99.3)	88.9 (43.3,98.4)	
<b>Centre</b>									
Newcastle (No at risk)	26	22	24	24	23	13	17	8	0.6957
% (95% CI)	92.3 (72.6,98.0)	95.5 (71.9,99.3)	91.7 (70.6,97.8)	100 (-)	95.7 (72.9,99.4)	100 (-)	100 (-)	100 (-)	
Leeds (No at risk)	101	59	73	63	60	68	65	37	0.5446
% (95% CI)	91.1 (83.6,95.3)	89.8 (78.8,95.3)	95.9 (87.8,98.7)	95.2 (86.0,98.4)	91.6 (81.0,96.4)	92.6 (83.1,96.8)	92.1 (82.96.6)	100 (-)	
Cambridge (No at risk)	67	61	58	28	50	39	52	26	0.0903
% (95% CI)	95.5 (86.8,98.5)	100 (-)	93.1 (82.7,97.4)	100 (-)	98 (86.6,99.7)	100 (-)	90.3 (78.3,95.9)	96.2 (75.7,99.4)	
Royal Free (No at risk)	82	80	88	50	61	64	65	37	0.4263
% (95% CI)	95.1 (87.5,98.1)	91.3 (82.5,95.7)	96.6 (89.7,98.9)	98.0 (86.6,99.7)	96.7 (87.5,99.2)	92.2 (82.2,96.7)	95.3 (86.1,98.5)		
Kings College (No at risk)	111	128	132	104	110	88	95	27	0.1121
% (95% CI)	98.2 (92.9,99.5)	96.8 (91.8,98.8)	98.5 (94.1,99.6)	96.0 (89.8,98.5)	96.3 (90.5,98.6)	96.5 (89.5,98.8)	97.9 (91.7,99.5)	85.8 (60.6,95.5)	
Birmingham (No at risk)	117	133	135	96	113	108	102	42	0.4947
% (95% CI)	93.2 (86.8,96.5)	94.7 (89.2,97.4)	95.5 (90.3,98.0)	95.8 (89.3,98.4)	92 (85.3,95.8)	92.6 (85.7,96.2)	97 (91.99)		
Edinburgh (No at risk)	75	84	45	55	37	38	30	15	0.6171
% (95% CI)	96 (88.1,98.7)	92.8 (84.7,96.7)	95.6 (83.4,98.9)	94.5 (84.0,98.2)	97.3 (82.3,99.6)	86.8 (71.2,94.3)	93.3 (75.9,98.3)	93.3 (61.3,99)	

\*20 March 2024 – 19 September 2024

**Table 22b** 1-year patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 September 2024

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25*	Log-rank p-value
<b>Overall (No at risk)</b>	183	177	166	103	183	239	249	140	0.5902
% (95% CI)	95.6 (91.4,97.8)	92.6 (87.6,95.7)	92.8 (87.6,95.8)	95.1 (88.6,97.9)	94.5 (90.0,97.0)	96.2 (92.8,98)	92.3 (88.95.1)	95.5 (90.3,98)	
<b>Type of patient</b>									
CLD (No at risk)	120	83	103	65	98	141	157	89	0.8709
% (95% CI)	96.7 (91.3,98.7)	92.8 (84.6,96.7)	95.1 (88.7,97.9)	95.3 (86.1,98.5)	94.9 (88.1,97.8)	96.4 (91.6,98.5)	93.2 (87.6,96.3)	96.3 (89.98.8)	
HCC (No at risk)	52	83	58	33	73	84	75	37	0.3996
% (95% CI)	92.2 (80.5,97.0)	92.7 (84.5,96.7)	87.9 (76.3,94.1)	93.9 (77.9,98.4)	95.8 (87.6,98.6)	97.6 (90.8,99.4)	90.1 (80.2,95.2)	94.6 (80.1,98.6)	
VS (No at risk)	9	4	1	2	8	12	12	11	0.8800
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	87.5 (38.7,98.1)	91.7 (53.9,98.8)	100 (-)	90.9 (50.8,98.7)	
HCC downstaging (No at risk)	2	7	4	3	3	2	4	2	0.6055
% (95% CI)	100 (-)	85.7 (33.4,97.9)	100 (-)	100 (-)	100 (-)	50.0 (0.6,91.0)	75 (12.8,96.1)	100 (-)	
<b>Recipient blood group</b>									
O (No at risk)	95	78	67	48	86	111	119	54	0.4073
% (95% CI)	96.8 (90.5,99.0)	92.3 (83.6,96.5)	94.0 (84.9,97.7)	95.7 (84.0,98.9)	94.1 (86.5,97.5)	97.3 (91.8,99.1)	90.1 (82.9,94.4)	96.3 (86,99.1)	
A (No at risk)	67	72	78	46	74	90	92	64	0.9113
% (95% CI)	95.4 (86.5,98.5)	95.8 (87.6,98.6)	91 (82.0,95.6)	95.7 (83.7,98.9)	94.6 (86.1,97.9)	95.5 (88.4,98.3)	94 (86.1,97.5)	95 (85.2,98.4)	
B (No at risk)	18	20	18	7	22	33	33	17	0.9867
% (95% CI)	94.4 (66.6,99.2)	90.0 (65.6,97.4)	94.4 (66.6,99.2)	85.7 (33.4,97.9)	95.5 (71.9,99.3)	93.9 (77.9,98.4)	93.9 (77.9,98.4)	94.1 (65,99.1)	


AB (No at risk)	3	7	3	2	1	5	5	5	0.5464
% (95% CI)	66.7 (5.4,94.5)	71.4 (25.8,92)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	
<b>Centre</b>									
Newcastle (No at risk)	4	3	4	2	13	14	25	8	0.9292
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	92.9 (59.1,99.0)	91.6 (70.4,97.8)	100 (-)	
Leeds (No at risk)	26	20	21	15	16	26	35	5	0.3768
% (95% CI)	92.3 (72.6,98.0)	90.0 (65.6,97.4)	85.7 (62.0,95.2)	100 (-)	93.3 (61.3,99.0)	100 (-)	85.3 (68.1,93.6)	100 (-)	.
Cambridge (No at risk)	30	37	31	29	43	52	47	21	0.7915
% (95% CI)	96.7 (78.6,99.5)	94.6 (80.1,98.6)	90.3 (72.9,96.8)	100 (-)	93 (79.9,97.7)	96.2 (85.5,99.0)	95.5 (83.2,98.9)	95.2 (70.7,99.3)	
Royal Free (No at risk)	13	28	36	11	22	18	30	19	0.7324
% (95% CI)	92.3 (56.6,98.9)	85.7 (66.3,94.4)	91.6 (76.1,97.2)	72.7 (37.1,90.3)	90.9 (68.3,97.6)	88.9 (62.4,97.1)	88.4 (67.5,96.2)	94.7 (68.1,99.2)	
Kings College (No at risk)	46	37	36	30	46	48	46	25	0.8921
% (95% CI)	95.5 (83.0,98.8)	94.6 (80.1,98.6)	97.2 (81.9,99.6)	93.1 (75.1,98.2)	100 (-)	95.8 (84.4,98.9)	95.6 (83.4,98.9)	96 (74.8,99.4)	
Birmingham (No at risk)	52	39	33	11	25	54	34	47	0.7453
% (95% CI)	96.2 (85.5,99.0)	92.3 (78.0,97.5)	97.0 (80.4,99.6)	100 (-)	96.0 (74.8,99.4)	98.1 (87.4,99.7)	90.2 (72.2,96.8)	95.7 (84.98.9)	
Edinburgh (No at risk)	12	13	5	5	18	27	32	15	0.2705
% (95% CI)	100 (-)	100 (-)	80.0 (20.4,96.9)	100 (-)	83.3 (56.8,94.3)	96.3 (76.5,99.5)	96.9 (79.8,99.6)	93.3 (61.3,99)	

\*20 March 2024 – 19 September 2024

3.8.4 **Figure 23** shows the unadjusted one-year transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first seventy-eight months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 1 year.

3.8.5 There were no statistically significant differences in the unadjusted one-year transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.92 and 0.73).

**Figure 23 Unadjusted one year transplant survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 September 2024**



## 4 CONCLUSIONS

The new National Liver Offering Scheme was implemented on the 20<sup>th</sup> March 2018 and updated on 4<sup>th</sup> October 2022. 6147 DBD and 6691 DCD livers were offered for transplantation in the first ninety months of the scheme. For DBD donors, the proportion retrieved ranged between 85% and 92% in the 90 months post and 88% in the year prior to NLOS. The equivalent proportion for DCD was 26% to 55% for the 90 months post and 32% in the year prior to NLOS.

## APPENDIX A: SUPER-URGENT CATEGORIES

### INDICATION FOR REGISTRATION

- 1 - Category 1: Aetiology: Paracetamol poisoning: pH <7.25 more than 24 hours after overdose and after fluid resuscitation
- 2 - Category 2: Aetiology: Paracetamol poisoning: Co-existing prothrombin time >100 seconds or INR >6.5, and serum creatinine >300 µmol/l or anuria, and grade 3-4 encephalopathy
- 3 - Category 3: Aetiology: Paracetamol poisoning: Significant liver injury and coagulopathy following exclusion of other causes of hyperlactatemia (e.g. pancreatitis, intestinal ischemia) after adequate fluid resuscitation: arterial lactate >5 mmol/l on admission and >4 mmol/l 24 hours later in the presence of clinical hepatic encephalopathy
- 4 - Category 4: Aetiology: Paracetamol poisoning: Two of the three criteria from category 2 with clinical evidence of deterioration (eg increased ICP,  $\text{FiO}_2$  >50%, increasing inotrope requirements) in the absence of clinical sepsis
- 5 - Category 5: Aetiology: Favourable non-paracetamol aetiologies such as acute viral hepatitis or ecstasy/cocaine induced ALF: the presence of clinical hepatic encephalopathy is mandatory and: prothrombin time >100 seconds, or INR >6.5, or any three from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; any grade of hepatic encephalopathy with jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 6 - Category 6: Aetiology: Unfavourable non-paracetamol aetiologies such as seronegative or idiosyncratic drug reactions: a) prothrombin time >100 seconds, or INR >6.5, or b) in the absence of clinical hepatic encephalopathy then INR >2 after vitamin K repletion is mandatory and any two from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; if hepatic encephalopathy is present then jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 7 - Category 7: Aetiology: Acute presentation of Wilson's disease or Budd-Chiari syndrome. A combination of coagulopathy and any grade of encephalopathy
- 8 - Category 8: Hepatic artery thrombosis on days 0 to 21 after liver transplantation
- 9 - Category 9: Early graft dysfunction on days 0 to 7 after liver transplantation with at least two of the following: AST >10,000; INR >3.0; arterial lactate >3 mmol/l; absence of bile production
- 10 - Category 10: The total absence of liver function (eg after total hepatectomy)
- 11 - Category 11: Any patient who has been a live liver donor (NHS entitled) who develops severe liver failure within 4 weeks of the donor operation
- 20 - Category 20: Acute liver failure in children under two years of age: INR >4 or grade 3-4 encephalopathy. Definition: Multisystem disorder in which severe acute impairment of liver function with or without encephalopathy occurs in association with hepatocellular necrosis in a child with no recognised underlying chronic liver disease. Children with leukaemia/lymphoma, haemophagocytosis and disseminated intra-vascular coagulopathy are excluded

## APPENDIX B: THREE MONTH REGISTRATION OUTCOME

Figure B1 Three month registration outcome for active elective liver and liver/kidney patients, by type of patient, 20 December 2014 to 19 June 2025







Figure B2 Three month registration outcome for active elective liver and liver/kidney patients, by age group, 20 December 2014 to 19 June 2025




**Figure B3 Three month registration outcome for active elective liver and liver/kidney patients, by first transplant or regraft, 20 December 2014 to 19 June 2025**



**Figure B4 Three month registration outcome for active elective liver and liver/kidney patients, by sex, 20 December 2014 to 19 June 2025**





## APPENDIX C: SIX MONTH REGISTRATION OUTCOME

Figure C1 Six month registration outcome for active elective liver and liver/kidney patients, by type of patient, 20 September 2014 to 19 March 2025




Figure C2 Six month registration outcome for active elective liver and liver/kidney patients, by age group, 20 September 2014 to 19 March 2025




Figure C3 Six month registration outcome for active elective liver and liver/kidney patients, by first transplant or re-graft, 20 September 2014 to 19 March 2025






Figure C4 Six month registration outcome for active elective liver and liver/kidney patients, by sex, 20 September 2014 to 19 March 2025





**Table D.1 Median (IQR; range) time to transplant (days) for named patient offers for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 September 2025, as at 10 October 2025**

Centre	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*
Newcastle (N)	-	20	21	21	20	13	13	13	5
Median (IQR)	-	43 (21.5, 97.5)	34 (16, 85)	40 (9, 136)	32.5 (12, 107.5)	8 (5, 12)	21 (9, 164)	29 (7, 56)	4 (2, 18)
Range	-	2 - 318	2 - 488	4 - 607	2 - 760	4 - 998	4 - 1233	4 - 485	2 - 31
Leeds (N)	-	58	60	54	52	69	62	65	32
Median (IQR)	-	41.5 (8, 130)	19.5 (8, 100.5)	25 (11, 105)	18.5 (9, 82)	21 (7, 124)	32 (11, 84)	57 (13, 164)	53 (11, 113)
Range	-	1 - 1341	1 - 662	1 - 1260	1 - 1187	1 - 1058	1 - 873	2 - 1454	2 - 1780
Cambridge (N)	-	49	42	21	38	35	46	34	14
Median (IQR)	-	31 (9, 67)	15 (5, 30)	11 (3, 23)	22.5 (6, 63)	14 (7, 62)	16 (8, 42)	14.5 (5, 68)	10 (5, 22)
Range	-	2 - 760	2 - 656	0 - 153	0 - 633	1 - 407	1 - 753	2 - 1285	2 - 1031
Royal Free (N)	-	67	61	41	57	50	44	43	24
Median (IQR)	-	20 (6, 100)	19 (8, 66)	27 (8, 74)	22 (5, 92)	27 (9, 78)	37 (8.5, 137)	23 (6, 94)	16 (7.5, 61)
Range	-	1 - 1261	1 - 971	2 - 669	2 - 592	2 - 1453	2 - 1004	1 - 985	2 - 316
Kings College (N)	-	110	111	90	104	84	80	67	43
Median (IQR)	-	37 (10, 235)	28 (7, 160)	26.5 (7, 131)	27 (8, 78)	64 (10, 260)	86.5 (23.5, 265)	83 (19, 377)	42 (6, 205)
Range	-	1 - 1711	1 - 1620	1 - 1687	1 - 968	2 - 2100	1 - 1286	1 - 1647	2 - 567
Birmingham (N)	-	119	108	69	88	92	90	60	39
Median (IQR)	-	35 (9, 92)	40 (7.5, 156.5)	28 (5, 107)	23 (7, 80)	49.5 (14.5, 172.5)	49.5 (15, 226)	67 (13.5, 203.5)	117 (6, 262)
Range	-	1 - 1657	1 - 865	1 - 1814	1 - 1470	1 - 1066	1 - 811	1 - 1556	2 - 1324
Edinburgh (N)	-	68	38	48	36	35	27	33	13
Median (IQR)	-	16.5 (5, 102.5)	39 (17, 98)	23 (9, 229)	21 (7, 37)	21 (8, 78)	80 (32, 204)	31 (16, 109)	39 (12, 82)
Range	-	1 - 1124	2 - 640	1 - 694	1 - 452	2 - 218	3 - 1401	2 - 1274	1 - 988

**Table D.2 Median (IQR; range) time to transplant (days) for fast-track offers for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 September 2025, as at 10 October 2025**

Centre	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*
Newcastle (N)	-	2	5	6	3	1	4	8	0
Median (IQR)	-	50 (4, 96)	21 (14, 64)	121.5 (22, 190)	88 (62, 130)	231 (231, 231)	81.5 (32.5, 389.5)	59.5 (19, 126.5)	-
Range	-	4 - 96	1 - 517	2 - 494	62 - 130	231 - 231	12 - 669	3 - 308	-
Leeds (N)	-	8	19	16	8	5	9	14	3
Median (IQR)	-	49.5 (21, 449)	93 (33, 187)	120.5 (61.5, 291)	119 (96.5, 170.5)	136 (46, 413)	206 (137, 414)	155 (81, 357)	76 (40, 108)
Range	-	6 - 566	3 - 1405	6 - 671	42 - 254	4 - 769	18 - 735	8 - 507	40 - 108
Cambridge (N)	-	16	18	14	12	5	6	11	6
Median (IQR)	-	65.5 (20.5, 258)	77 (15, 167)	46 (25, 212)	91 (56.5, 147)	16 (12, 139)	64.5 (5, 147)	69 (31, 237)	129 (77, 363)
Range	-	1 - 583	1 - 603	9 - 679	26 - 191	1 - 311	2 - 676	17 - 530	38 - 422
Royal Free (N)	-	16	30	16	8	18	24	30	11
Median (IQR)	-	106.5 (40, 244.5)	72.5 (37, 153)	61 (27, 260.5)	220.5 (86.5, 399)	112 (51, 440)	104 (34, 297.5)	100 (50, 278)	95 (23, 148)
Range	-	3 - 547	1 - 734	0 - 621	13 - 557	8 - 523	5 - 869	2 - 449	1 - 177
Kings College (N)	-	33	34	25	13	14	23	16	13
Median (IQR)	-	98 (29, 252)	97.5 (58, 193)	60 (19, 140)	107 (34, 315)	180.5 (111, 293)	145 (58, 263)	95 (33, 248.5)	45 (18, 196)
Range	-	1 - 605	6 - 465	0 - 512	3 - 689	4 - 1103	3 - 1105	7 - 1074	0 - 801
Birmingham (N)	-	35	46	45	39	23	20	19	5
Median (IQR)	-	93 (22, 150)	129 (32, 476)	194 (65, 405)	122 (33, 282)	260 (68, 500)	162 (104, 452.5)	375 (47, 549)	202 (50, 1032)
Range	-	1 - 937	0 - 976	1 - 1593	1 - 1400	1 - 2223	30 - 1420	3 - 1400	5 - 1474
Edinburgh (N)	-	20	14	10	3	5	4	2	3
Median (IQR)	-	42.5 (12.5, 192.5)	106 (46, 178)	84 (52, 324)	13 (2, 51)	30 (23, 31)	29.5 (23.5, 84.5)	290 (150, 430)	19 (10, 50)
Range	-	2 - 621	10 - 310	4 - 749	2 - 51	6 - 57	18 - 139	150 - 430	10 - 50

\*includes transplants up to 19 September 2025